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1.  Introduction 
 
1.1  Brain: The different cell types and their functions 
The brain is composed of mainly two classes of cells, neurons and glia. Glial cells outnumber 
neurons by 10:1 (sfn.org; Society for Neuroscience, 2000). So far, studies on brain function 
have been mainly focused on the effects of toxic and degenerative processes on the survival of 
neurons because of their crucial involvement in the chemical and electrical transmission of 
information between cells and over long distances. However, with course of time, glial cells too 
have emerged as new focus. Glial cells are non-neuronal cells that fulfill a large number of 
various functions including the formation of the blood-brain-barrier, providing nutrients and 
growth factors to the nervous tissue, and playing a principal role in repair processes in the brain 
and spinal cord following traumatic injuries (Davies et al. 2006).  
Astrocytes belong to the class of glial cells and are characterized by a star-shaped morphology. 
They form close contacts to neighboring cells, like other astrocytes, blood vessel, neurons, and 
synaptic clefts by enwrapping these structures with their processes. There is a growing body of 
evidence that astrocytes provide many different and essential functions to support neuronal 
survival (Jourdain et al. 2007; Pellerin et al. 2007). Astrocytes also play an important role in 
neurodegenerative diseases. It is well-acknowledged that interactions between neurons and 
astrocytes occur and are critical for cell-cell signaling, energy metabolism, extracellular ion 
homeostasis, volume regulation, and neuroprotection in the central nervous system (Bezzi et al. 
2001; Haydon et al. 2001) For instance, astrocytes were shown to protect neurons against 
glutamate toxicity (Rosenberg and Aizenman, 1989) and peroxide generation (Deshagar et al. 
1996). Astrocytes do express proteins that are necessary for the uptake of glutamate at synapses, 
ammonia detoxification, buffering of extracellular K+, and volume regulation (Hertz et al. 2004; 
Newman et al. 2003). Astrocytes are also responsible for detection, propagation, and modulation 
of excitatory synaptic signals (Maragakis and Rothstein, 2006). With respect to the high energy 
demand of neuronal signaling processes, astrocytes provide an essential metabolic support to the 
neurons, thereby sustaining brain activity.  
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            Fig. 1 Functional diversity of astrocytes (1) Astrocyte functions include the modulation of synaptic 
function via glutamate transporters, which remove glutamate from the synaptic cleft into the cell. (2) 
Communication between astrocytes occurs via release and binding of ATP to purine receptors on 
adjacent astrocytes. ATP binding results in phospholipase C activation with subsequent downstream 
activation of inositol triphosphate resulting in calcium mobilization. (3) Gap junctions contribute to an 
astrocyte syncytium for the exchange of small molecules and cell–cell-communication. Metabolic 
functions include (4) the replenishment of neuronal glutamate via the glutamate–glutamine-cycle, and 
(5) the transport of glucose from the vasculature to neural cells. (6) The regulation of blood flow is 
modulated by astrocyte end-feet enwrapping blood vessels including vasodilation being mediated by the 
release of vasoactive substances. (7) Glutamate release might occur following elevations in intracellular 
calcium and the activation of other factors related to prostaglandins. (8) Glutamate release through 
hemichannels can be induced in vitro through lowering the extracellular calcium concentration. (9) 
Glutamate binding to metabotropic glutamate receptors activates intracellular calcium leading to the 
release of vasodilatory substances. Abbreviations: Gln, glutamine; Glu, glutamate; IP3, inositol 
triphosphate; PLC, phospholipase C (modified from Maragakis and Rothstein, 2006).  
 
 
1.2  Neurodegeneration and brain region specificity 
          Neurodegeneration implies an impairment of neuronal function culminating often in a 
progressive loss of neurons. Many neurodegenerative diseases including Huntington’s, 
Parkinson’s, and Alzheimer’s disease occur as a result of progressive loss of neurons affecting 
different brain regions to a different extent. Huntington’s disease causes astrogliosis and a loss of 
medium spiny neurons in the striatum (Vonsattel et al. 1985; Brouillet et al. 1999, Vis et al.1999). 
Neural cells in the striatum are mainly affected, but cells of the frontal and temporal cortices are 
also involved (Selemon et al. 2003). Alzheimer's disease is characterized by a loss of neurons in 
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the cerebral cortex, especially the temporal and parietal lobe, and certain sub-cortical regions 
(Wenk, 2003). In Parkinson’s disease, a decreased stimulation of the motor cortex by the basal 
ganglia is caused by a deficiency of dopaminergic neurons in the brain. The role of astrocytes in 
neurodegenerative diseases by propagating the toxic effect to neurons has been shown by many 
studies (Satoia et al. 2005; Harris et al. 2003; Nagai et al. 2007).  
      
1.3  Huntington’s disease 
1.3.1 Huntington’s disease - The in vivo model 
          Huntington's disease (HD) is a hereditary neurodegenerative disorder which is characterized by 
un-coordinated, jerky body movements and decay in mental performance. Genetically, HD 
appears due to an expansion of the CAG repeats in the huntingtin gene which is located on 
chromosome 4 (Brennan et al. 1985). The protein huntingtin (htt) is expressed in both the 
peripheral and central nervous system. Although the physiological function of huntingtin and its 
role in the pathogenesis of neuronal degeneration in Huntington’s disease are obscure, 
substantial evidences suggest that the mutation within the same directs to a cell type-specific 
neuronal degeneration. The cell death occurs predominantly in the striatum affecting the 
GABAergic neurones and also the deep layers of the cerebral cortex (Ferrante et al. 1987; de la 
Monte et al. 1988; Martin and Gusella, 1986). The early pathogenesis of HD comprises the 
selective loss of medium-size spiny neurons in the striatum and reactive gliosis (Vonsattel et al. 
1985, 1998). A study on HD revealed that interaction of neurons with glial cells, especially 
astrocytes, promotes neuronal survival. Co-culturing of primary neurons with astrocytes 
expressing wild-type huntingtin protein protects these neurons against neurotoxicity, whereas 
glial cells expressing mutant huntingtin increased neuronal vulnerability (Shin et al. 2005). 
These observations indicate that mutant huntingtin in glial cells can contribute to neuronal 
dysfunction and excitotoxicity in HD brains through dysfunction of astroglial cells. Among 
other important functions, astrocytes provide for and regulate energy homeostasis under normal 
conditions but appear to be particularly involved in the modulation of energy metabolism under 
pathological conditions in the central nervous system. 
 
1.3.2 Application of 3-nitropropionic acid (NPA) – The in vitro model  
The application of 3-nitropropionic acid (NPA), an irreversible inhibitor of succinate 
dehydrogenase, is used as an in vitro model of Huntington’s disease to study mechanisms of 
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mitochondrial dysfunction under neurodegenerative conditions. Systemic administration of NPA 
in both, rodents and primates, produces selective basal ganglia lesions and dystonia 
accompanied with movement disorder as well as frontal type cognitive deficits which are similar 
to those occurring in HD (Beal 1998, 2005). NPA exerts its toxicity causing neuronal cell death 
by an impairment of the energy metabolism which is reflected in a reduction of ATP (Ludolph 
et al. 1992; Behrens et al. 1995). Paradoxically, increased ATP levels were also detected in HD 
brain tissue (Olah et al. 2008). As suggested, NPA mainly leads to apoptotic cell death (Behrens 
et al. 1995), but a few studies have disclosed a non-apoptotic death mode in HD transgenic mice 
brain (Turmaine et al. 2000). Furthermore, necrotic cell death was increased as a consequence 
of acute excitotoxic processes in HD brains and NPA-treated neural cells (Sawa et al. 2003; 
Geddes et al. 2000). Although, energy impairment by blocking complex II activity is considered 
responsible for this, the role of other complexes should also be taken into account with respect 
to the inconsistency of results obtained for respiratory chain enzyme activities in HD. The 
existence of controversial data suggests the requirement for more studies in this context. 
 
1.3.3   Impairment of mitochondrial function in Huntington’s disease 
          Mitochondria are dynamic organelles that provide energy to cells by the transport of electrons 
through the respiratory chain. Many evidences indicate that mitochondrial dysfunction is 
associated with perturbed energy metabolism which is one of the fundamental mechanisms 
involved in cell degeneration. Generally, mitochondrial dysfunction is accompanied by a 
decreased energy production due to an inhibition of respiratory chain complexes. This, 
consequently, leads also to an impaired mitochondrial calcium buffering and elevated generation 
of reactive oxygen species (ROS; Saulle et al. 2004; Beal 2005; Seong et al. 2005; Brouillet et al. 
2005). Under resting conditions, between 2 and 5% of the molecular oxygen consumed by 
mitochondria is converted into superoxide and hydrogen peroxide by the mitochondrial 
respiratory chain. In turn, mitochondrial ROS impairs the enzyme activity of one or more of the 
components of the respiratory chain, thereby accelerating further the rate of superoxide formation 
(Turrens and Boveris, 1980) and provoking either apoptotic or necrotic cell death. Previous 
studies suggested that mitochondrial dysfunction participates in aging, metabolic diseases, and 
neurodegeneration (Beal 1997). There is a growing body of evidence that mitochondria play a 
crucial role in neurodegenerative and toxic processes (Beal 2005; Ayala et al. 2007). Obviously, 
an impairment of mitochondrial function occurs quite early in the course of HD and has been 
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observed in transgenic models of the disorder (Koroshetz et al. 1997; Jenkins et al. 1999; Sawa et 
al. 1999; Panov et al. 2002). Evidences in support of a mitochondrial involvement also include 
reports about structural and functional changes of enzymes participating in oxidative 
phosphorylation. Patients diagnosed with Huntington’s disease exhibited a complex II 
impairment (Butterworth et al. 1985), but did not show any changes in complex I or IV activity 
(Mann et al. 1990). However, a study performed on platelets of HD patients revealed no changes 
in the activity of complex II or III, but in complex I (Parker et al. 1990). Investigations carried 
out on fibroblasts from HD and control patients highlighted mitochondrial defects related to their 
Ca2+ buffering capacity. However, in vivo NMR measurements of ATP, lactate, creatine, and 
phosphocreatine levels in HD patients are conflicting (Jenkins et al. 1993; Sanchez-Pernaute et 
al. 1999; Hoang et al. 1998).  In a recent study (Montoya et al. 2006), striatal glucose metabolism 
has also been reported to participate in HD by showing normal or reduced metabolism in pre-
symptomatic HD individuals, whereas striatal hypometabolism has been observed consistently in 
symptomatic HD patients. Cortical hypometabolism has also been seen in early stage and 
symptomatic HD patients with positron emission tomography or single-photon emission 
computed tomography (Ma and Eidelberg 2007). During recent years, the research of HD has 
developed extensively. However, the exact mechanisms underlying the degenerative processes 
remain obscure. The mitochondrial mechanisms of HD have yet to be elucidated.  
 
1.4  The role of mitochondria in neurodegenerative diseases 
            Like HD, there are other neurodegenerative diseases including Parkinson’s disease (PD) and 
Alzheimer’s disease (AD) that are related to mitochondrial dysfunction due to the inhibition of 
the activity of respiratory chain complexes (Petrozzi et al. 2007). In Alzheimer’s disease, 
deficient cytoctrome c oxidase (COX) activity was reported in different brain regions by several 
authors (Bosetti et al. 2002; Kish et al. 1992). In case of Parkinson’s disease, complex I was 
significantly affected leading to a loss of dopaminergic neurons (Hattori et al. 1991; Schapira, 
2006). 
            With respect to the role of astrocyte energy metabolism for neuronal survival in HD and NPA-
mediated toxicity, many questions are left unanswered. Considering COX as an important 
regulatory site of the mitochondrial respiratory chain, this enzyme may play a crucial role under 
different neurodegenerative and ischemic conditions (Kish et al. 1992; Bosetti et al. 2002; 
Kadenbach et al. 2004; Horvat et al. 2006; Singh et al. 2009). 
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1.5  Cytochrome c oxidase (COX) 
          Cytochrome c oxidase (EC 1.9.3.1, COX) is the terminal enzyme of the respiratory chain and 
located in the inner mitochondrial membrane. It transfers four electrons from cytochrome c to 
oxygen producing water. This process is accompanied by the translocation of protons across the 
membranes, which are subsequently used by the ATP synthase to convert ADP into ATP, the 
major energy substance in cells. Structurally, COX consists of a variable number of subunits in 
different species. Enzyme from the bacterium Paracoccus denitrificans consists of four subunits, 
three of which correspond to the mitochondria-encoded subunits of the eukaryotic enzyme 
(Bisson and Schiavo, 1986). Cytochrome-c Oxidase from Saccharomyces cerevisiae exhibited 
the structure made of 11 subunits (Geier et al. 1995). Previous review articles postulated that the 
increasing number of subunits during evolution reflects an increasing regulatory complexity of 
the enzyme (Kadenbach et al. 1986). But, in past few years regulatory functions were identified 
for some nuclear-coded subunits of the mammalian enzyme. These results gained strong support 
from the recently determined crystal structures of cytochrome c oxidase from bovine heart. 
Mammalian COX is composed of 13 subunits (Tsukihara et al. 1996). Three of these subunits are 
encoded by mitochondria and are responsible for the catalytic reaction, whereas the other ten 
subunits are encoded by the nucleus and fulfill regulatory functions. These regulatory subunits 
are expressed as isoforms in a tissue-specific manner. The mitochondria-encoded subunits (I-III) 
of COX contain the catalytic redox centers CuA, heme a, and heme a3/CuB (Tsukihara et al. 
1995).  
 
1.5.1 Enzyme reaction  
 4 Fe2+-cytochrome c + 8 H+matrix+ O2 → 4 Fe3+-cytochrome c + 2 H2O + 4 H+cytosol 
          Cytochrome c binds to the CuA center which is present in subunit II, whereas oxygen is reduced 
to water at the binuclear heme a3/CuB center located in subunit I. COX catalyzes the electron 
transfer from ferrocytochrome c to oxygen, a process that is coupled to the translocation of 
protons across the inner mitochondrial membrane. This proton gradient is used to produce ATP 
through the F0F1-ATP synthase. 
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Fig. 2 The crystal structure of cytochrome c oxidase from bovine heart Each monomer of the 
dimeric enzyme contains three mitochondria-encoded subunits (I-III, green-yellow backbone) 
containing the cytochrome c binding site and two copper atoms (CuA) in subunit II. Heme a and the 
oxygen binding site are located at the binuclear centre heme a3/CuB in subunit I. Subunit IV and the 
ATP/ADP binding site, is depicted in red (adapted from Kadenbach et al. 2000). 
 
           
1.5.2 Enzyme subunit IV and its isoforms    
            Subunit IV of COX is one of the regulatory subunits which are encoded by the nucleus. COX 
subunit IV plays a crucial role in the regulation of the enzyme by adenine nucleotides. At high 
levels of intracellular/intra-mitochondrial ATP, this subunit binds ATP to the matrix domain. 
This causes an allosteric inhibition of COX activity accompanied by a change of COX kinetic 
features from a hyperbolic (low ATP/ADP ratio) to a sigmoidal curve (high ATP/ADP ratio). A 
complete inhibition of COX activity was observed at cytochrome c concentrations of 1-6 µM, 
which are accepted to fall into the physiological range (Arnold and Kadenbach, 1997, 1999; 
Horvat et al. 2006). This phenomenon was explained as “second mechanism of respiratory 
control”. It was found to be independent of the proton gradient and enables the enzyme to sense 
the energy level (ATP/ADP ratio) and to adjust it to cellular energy demands (Arnold and 
Kadenbach, 1997, 1999; Horvat et al. 2006).  
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           With respect to this regulatory function of COX subunit IV, the occurrence of isoforms of this 
subunit challenges a different role for COX regulation and consequently, for cell energy 
production and survival. Two isoforms of COX subunit IV (IV-1 and IV-2) were detected in 
yeast tuna fish, and mammals (Poyton et al. 1995; Hüttemann et al. 2001). COX isoform IV-1 
and IV-2 are approximately 50% homologous. Structural differences are mainly located at the 
termini of the isoforms. Subunit isoform IV-1 is ubiquitously transcribed in all mammalian 
tissues, whereas COX isoform IV-2 shows high transcription levels in adult human and rat lung 
as well as in human fetal lung and fetal muscle. In brain tissue, a predominant expression of COX 
isoform IV-1 was detected (Horvat et al. 2006). Among brain cells, astrocytes express primarily 
COX IV-1, whereas neurons revealed also the presence of COX IV-2 transcripts (Horvat et al. 
2006, Singh et al. 2009). The expression of COX subunit IV isoforms is regulated by the oxygen 
concentration. This has been shown for yeast and mammals.  In yeast, the homologous to 
mammalian COX subunit IV isoforms Va and Vb are present (Capaldi et al. 1986). Under 
normoxic conditions, COX isoform Va is expressed, whereas COX isoform Vb is transcribed at 
low oxygen concentration (below 0.5 M O2) (Burke et al. 1997; Kwast et al. 1998). The yeast 
COX complex comprising the isoform Vb displays an accelerated internal electron transfer step 
from heme a to heme a3 resulting in a higher turnover number (Allen et al. 1995). For the 
mammalian enzyme, a similar regulatory mechanism was described (Horvat et al. 2006). When 
COX isoform IV-1 is expressed, the enzyme is rendered sensitive towards the cellular energy 
level and enabled to couple the rate of ATP production to energetic requirements by the allosteric 
inhibition of the enzyme at high ATP/ADP levels (Arnold and Kadenbach 1997, 1999; Horvat et 
al. 2006). COX IV-2, on the contrary, abolishes this regulatory mechanism. This was shown for 
COX from astrocytes, which expresses COX IV-1 under physiological conditions. However, 
under hypoxic conditions, a switch is observed from COX isoform IV-1 to COX IV-2, which 
prevents the COX regulation by ATP (Horvat et al. 2006). Although COX is known to be 
regulated by oxygen concentration (Wilson et al. 1994; Kwast et al. 1998; Horvat et al. 2006), 
effects of mitochondrial toxins on COX subunit IV isoform expression pattern and activity were 
not demonstrated so far. Therefore, a study on the regulation of COX subunit IV isoforms in 
different brain cell types, specifically in astrocytes and neurons, was performed after application 
of the mitochondrial toxin 3-nitropropionic acid (NPA).  
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1.6 Aims of the thesis  
            It is well-known that an impaired mitochondrial function is caused by dysfunction of respiratory 
chain complexes. This, in turn, may cause symptoms of neurodegenerative diseases. COX, the 
terminal enzyme of the respiratory chain, plays an important role in the regulation of energy 
metabolism. I, therefore, decided to explore the structural and functional characteristics of COX, 
focussing on the regulatory COX subunit IV and its isoforms in primary cultures of astrocytes 
and neurons upon treatment with NPA, a mitochondrial toxin and in vitro model of Huntington’s 
disease. I tried to answer the following questions: 
 
? How does NPA affect COX subunit IV isoform transcription in astrocytes? Is there a 
switch between COX subunit IV isoforms in astrocytes induced by NPA? With respect to 
NPA being used as an in vitro model of HD, I focussed mainly on striatal brain cells. 
 
? How does a change in COX subunit IV isoforms affect the enzyme activity? Is there an 
allosteric inhibition of COX in the presence of high ATP/ADP levels in presence of COX 
IV-1, and is it abolished when COX IV-2 is expressed? 
 
? What effects does NPA exert on the intracellular ATP content, mitochondrial ROS 
production, and cell viability in the context with the COX subunit IV isoform expression 
pattern? 
 
? What role do COX subunit IV isoforms in astrocytes compared with neurons play for a 
higher vulnerability of the striatum in comparison with the cortex upon NPA treatment? 
 
                      Overall, this study was aimed to investigate the role of COX and regulation of 
mitochondria function in HD using the NPA-mediated in vitro model of the disease. For 
completion of the project, I myself performed and analyzed most of the essential experiments and 
have been supported by Magdalena Misiak for establishment of siRNA technique to knock-down 
COX IV-2.  
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2. Materials and methods  
 
2.1  Cell culture 
To study the influence of mitochondrial toxin NPA in astrocytes and neurons, I prepared primary 
astrocytes and neuronal cultures from mouse brains. BALB/c mice were purchased from Harlan 
Winkelmann GmbH (Borchen, Germany). All procedures were performed in strict accordance 
with the published welfare rules for the care and use of laboratory animals at the University 
Clinics Aachen and the government of the State of Nordrhein-Westfalen, Germany. 
 
2.1.1   Preparation of primary astrocytic culture 
Primary astrocytes were prepared from BALB/c mice at postnatal day 1. Brains from decapitated 
mice were removed and transferred in preparation buffer consisting of 10 mM HEPES, 154 mM 
NaCl, 10 mM glucose, 2 mM KCl, and 15 µM BSA. Striatum was dissected from the brain of 
pups and meninges were removed. The dissected brain part was transferred to 5 ml of PBS 
containing 0.1% (v/v) trypsin and 0.02% (w/v) EDTA for 15 min and incubated for 15 min at 
room temperature. Subsequently, the tissue was transferred in DMEM with 16% (v/v) FCS and 
minced with the help of pasteure pipette. The dissociated tissue was filtered though 50 µl nylon 
mesh to new falcon and centrifuged for 4 min at 300 g at RT. The supernatant was discarded and 
pellet was dissolved in 10 ml of DMEM containing 16%FCS. Finally obtained cell suspension, 
was plated onto poly-L-ornithine (PLO) coated cultured dishes containing complete DMEM 
(Table 2.1). Cultures were maintained at 37°C in a humidified atmosphere of 95% air/5% CO2. 
Before reaching confluence, astrocytes were trypsinized and plated at lower density. Sub-
confluent astrocytes were incubated in neurobasal medium (NBM) for 48 hours and subsequently 
used for experiments.  
 
2.1.2 Preparation of primary neuronal cultures 
Primary cortical and striatal neurons were prepared from Balb/c mouse embryos at 16/17 days of 
gestation and cultured as described by Brewer  1995; Kajta et al 2004 with some modifications. 
Briefly, pregnant Balb/c female mice at gestation period of 16/17 days were killed by cervical 
dislocation. For purpose of preparing neurons, embryos were used. Cortical and striatal tissues 
were separated from fetal brains and dissected. The dissected brain regions were made free of 
meninges and minced into small pieces. Subsequently, the minced tissue were digested with 0.1% 
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trypsin (v/v) and 0.02% EDTA(w/v) for 15 min in 37°C, titurated in the presence of 20% heat-
inactivated fetal calf serum and DNAse I (70 units/ml) and finally centrifuged for 5 min at 1,000 
x g. The cells were resuspended in complete NBM. (Refer to table 2.1) Thereafter, cells were 
plated onto PLO-coated multi-well plates at a density of 1.5-2 x 105 cells per cm2. Neurons were 
grown at 37°C in a humidified incubator with 5% CO2. After 24h, the medium was changed to 
NBM without fetal calf serum (FCS). Medium was changed every second day. This typically 
yields cultures that contain >90% neurons <10% supporting cells. 
       
       Table 2.1 Composition of cell culture media 
       Complete DMEM for astrocytes 
Ingredients Amount/Concentration Company 
DMEM 500 ml PAA Labratories 
FCS 16% (v/v) PAA Labratories 
L-glutamine (Glutamax®) 2 mM Invitogen 
Penicillin/Streptomycin 50 U/ml, 50 µg/ml Biochrom AG 
Amphotericin B (Fungizone®) 0.25 µg/ml Invitrogen 
 
       Complete NBM for astrocytes 
Ingredients Amount/Concentration Company  
NBM 500 ml Gibco 
B27 0.2% (v/v) Invitrogen 
L-Glutamine (Glutamax®) 2 mM Invitrogen 
Penicillin/Streptomycin 50U/ml, 50µg/ml Invitrogen 
Amphotericin B (Fungizone®) 0.25 µg/ml Invitrogen 
 
       Complete NBM for neurons 
Ingredients Amount/Concentration Company  
NBM 500 ml Gibco 
FCS 10% (v/v) PAA Laboratories 
B27 0.4% (v/v) Invitrogen 
L-Glutamine (Glutamax®) 2 mM Invitrogen 
Penicillin/Streptomycin 50 U/ml, 50µg/ml Invitrogen 
Amphotericin B (Fungizone®) 0.25 µg/ml Invitrogen 
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2.1.3 Transfection and small interference (siRNA)-mediated knock-down  
Transfection was performed for gene-silencing using small interference RNA (siRNA). The 
antisense approach to gene silencing involves RNA sequence complementary to mRNA 
transcribed from a target gene. Antisense and sense RNAs block translation and the production of 
an encoded protein. For this purpose, striatal primary astrocytes, at first passage were cultured in 
complete DMEM. After reaching confluence of approximately 70%, the culture medium was 
changed to complete NBM. Transfection of astrocytes with small interference RNA (siRNA, 
Ambion, Hundingdon, UK) was carried out after 48 h incubation in NBM and reaching a 
confluence of approximately 85%. To achieve the knock-down of COX subunit IV-2 isoform, 
siRNA against COX IV-2 was applied (siRNA ID 175412 and 175413, 5’-
CCAUCGCUCCAACGAAUGGtt-3’ and 5’-GCGAGUCUAUGUGUUCCCUtt-3’ respectively). 
siRNA transfection was performed by using a final siRNA concentration of 20 nM and 1.5 µl 
lipofectamine RNAiMAX (Invitrogen), both diluted in serum-free OptiMEM I (Invitrogen). As a 
non-targeting control, silencer GAPDH siRNA (Silencer GAPDH siRNA Human, Mouse, Rat, 
Ambion, UK) and siRNA negative control were used for transfection. Transfection medium was 
changed to NBM after incubation for 24 h and cells were kept for additional 48 h in the presence 
or absence of NPA.  
 
2.2 Cell treatment and staining 
Primary astrocyte and neuronal cultures placed on culture dishes at 37°C in a humidified 
atmosphere of 95% air/5% CO2 in the presence of NBM were treated with different 
concentrations of nitropropionic acid (NPA) for the time indicated. Cells of the same preparation 
maintained under the same conditions except for NPA treatment served as controls. 
 
2.2.1 Immunocytochemistry 
To verify the presence of pure astrocytic and neuronal culture and distinguish the morphological 
changes in cortical versus striatal neurons in control and treated condition, immunocytochemistry 
was performed with astrocytic and neuronal marker respectively. Cells were grown on PLO 
coated coverslips (Menzel, Braunschweig, Germany) till they reached 80-90% confluency and 
incubated with 2µg/ml Hoechst 33342 Trihydrochlorid (Hoechst; Invitrogen) in culturing 
medium for 10 min in culturing condition. Samples were washed with 1X PBS twice and 
followed by fixation of the cells with 4% formaldehyde (Merck) for 30 min at room temperature. 
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Fixed cells were treated with 0.2% triton X 100 (Merck) for 15 min and then transferred to 3% 
BSA solution for 20 min to block the interactions with unspecific proteins. After that, blocking 
solution was removed and cells were exposed to the primary antibody diluted in BSA and 
incubated over night at 4oC. For concentration see Table 2.2. After incubation, the unbound 
primary antibodies were removed by rinsing the cells for 2-3 times for 5 min each in PBS. 
Secondary antibody was diluted in BSA solution and cells were incubated with that at room 
temperature for 2 h. All the incubations were performed in darkness to protect flurophores from 
bleaching. Subsequently, the cells were thoroughly rinsed to remove unbound secondary antibody 
at room temperature. Coverslips were then mounted in mounting medium. For this purpose, 
excess buffer was carefully removed with tissue paper and the coverslips were mounted upside 
down in a drop of mounting medium on a microscopy slide. Air bubbles were removed by 
pressing the coverslips gently. The slides were kept in 4oC till they get dried and then used for 
observation. Cells were observed under 40x objective with inverted microscope (Axiovert200M, 
Zeiss, Cologne, Germany), assembled with software Axiovision 3.1 at the excitation filter setting 
of 450-470 nm, 515-565 nm and 365/12 nm for Alexa flour 488 , Cy3 and Hoechst  respectively. 
             
            Table 2.2: Primary and secondary antibodies for immunocytochemistry 
 
 
Antibody Manufacturer concentration 
Rabbit polyclonal  anti-GFAP Encor 1:1,000 
Mouse monoclonal NeuN (MAB377) Chemicon 1:50 
Mouse monoclonal Pan-Neuronal 
Markers: SMI 311 and SMI 312 
Convenance 1:1,000 
Alexa fluor 488 donkey anti-mouse 
(Secondary) 
Invitrogen 1:500 
Alexa fluor 488 donkey anti-rabbit 
(Secondary) 
Invitrogen 1:500 
Cy3-conjugated affinity-purified anti-
rabbit IgG (Secondary) 
Jackson Immuno 
Research 
Laboratories 
1:300 
Cy3 goat anti-mouse IgG (Secondary) Chemicon 1:300 
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2.2.2    Hoechst and propidium iodide staining 
To determine the cell viablity and mode of cell death by apoptosis or necrosis process, I applied 
the following method. 1µl of YO-PRO1 (Invitrogen, Karlsruhe, Germany) in 300 µl of culturing 
medium was added for 40 min followed by the addition of 2 µg/ml Hoechst and incubation for 10 
min under culturing condition. Cells were rinsed with PBS twice to wash out excess staining. 
Samples were fixed with 100% ice-cold methanol in -20oC for 10 min, followed by washing steps 
with 1X PBS and incubation in 0.1% triton X 100 for 10 min at room temperature. Permeablized 
samples were transferred to 2x SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0) buffer for 20 
min. Solution of propidium iodide (invitrogen) was prepared by diluting the 1 mg/ml (1.5 mM) 
stock solution 1:3,000 in 2x SSC. Cells were incubated with the diluted stain for 10 minutes and 
rinsed with PBS twice for 5 min. Cells were mounted in moviol and kept in 4oC to dry. Normal, 
apoptotic (Hoechst- and YO-PRO-1 positive), and necrotic (Hoechst-, YO-PRO-1-, and PI-
positive) cell nuclei were scored under a fluorescence Axiophot microscope (Carl Zeiss) at 
excitation wavelength of 365 (Hoechst), 485 (YO-PRO-1), and 530 nm (PI). Cell nuclei were 
counted in three separate experiments by counting cells in three distinct randomly selected areas 
per coverslip using the NIS-elements AR 3.0 ® software (Nikon).  
 
2.2.2 Trypan blue staining for astrocytic culture 
Cells were taken out after treatment, washed with PBS and trypsinised with 0.1% trypsin/EDTA. 
Cells were centrifuged at 300g for 5 min and pellet was resuspended in complete culture 
medium. 20µl of suspension was taken and mixed with 5µl of trypan blue. The mixture was left 
for incubation for 10 min and the cells were counted per ml with the help of haemocytometer by 
using the following formula.   
  
Cells per ml = the average count per square x the dilution factor x104 
 
2.2.3 Trypan blue staining for neurons  
Determination of cell viability in neurons was done by trypan blue staining of axons of dead 
neurons which retain the color of the dye.  Cells were plated in 48 well plates and treated and un-
treated neurons were washed with PBS. Thereafter, they were immediately stained with 0.1% 
(w/v) Trypan Blue solution (Fluka) for 10 min and fixed with 0.4% paraformaldehyde for 10 min. 
Afterwards, fixed cells were washed again twice with PBS and counted. Cell viability was 
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calculated as percentage of the ratio of unstained (viable) cells to the total number of cells 
(stained and unstained cells). Cells were counted from three distinct areas of three independent 
cell preparations. Viability of control cells was referred to as 100%. 
 
2.3 Molecular biology  
2.3.1   RNA isolation  
Cells were taken out of the incubator, washed with 1X PBS/EDTA and scraped with the 
PEQGOLD RNA pure (Peqlab) in culture dish. After 5-10 min of incubation at room 
temperature, chloroform was added in order to separate RNA from DNA and proteins and kept 
on incubation for 10 min at room temperature after brief vortexing. Subsequently, centrifugation 
was carried out for 10 min at 4°C at 12,000g and the obtained aqueous RNA phase was pipetted 
in a tube. To precipitate RNA, isopropanol was added and incubated for 20 min on ice. The next 
step was carried out with centrifugation at 4°C at 12,000g for 40 min. Having removed 
supernatant, pellet was washed with 75% ice-cold ethanol with centrifugation at 4°C at 12,000g 
for 30 min.  The washed pellet was dried and 12 µl of DEPC water was added to it. To resuspend 
the pellet, the samples were incubated at 50˚C in thermo-mixer with continuous shaking for 10 
min. Estimation of RNA concentration in the sample was measured photometrically at 260 nm by 
using BioPhotometer (Eppendorf). RNA integrity was tested randomly by 1% (w/v) agarose 
denaturing gel electrophoresis and ethidium bromide staining and visualized under UV-
illumination. First strand complementary DNA (cDNA) was synthesized from 1 µg total RNA.  
 
2.3.2 Reverse transcription 
First strand complementary DNA (cDNA) was synthesized from 1 μg total RNA. In brief, total 
RNA dissolved in 14 μl DEPC H2O was pre-incubated at 95°C for 5 min and placed immediately 
on ice. Subsequently, the reaction buffer consisting of 8 U/μl SuperScriptTM III Reverse 
Transcriptase, 4 mM dithiotreitol, 40 mM Tris-HCl, 60 mM KCl, and 2.4 mM MgCl2  
(Invitrogen), and 0.4 mM each dNTP (Roti-mix®PCR3, Roth, Karlsruhe, Germany) was added to 
RNA giving a final volume of 25 μl. After incubation for 40 min at 55°C, reverse transcription 
was stopped by heat-inactivating the enzyme at 70°C for 20 min. Addition of water instead of 
RNA served as negative control. Transcripts of 18S ribosomal RNA (18S rRNA) served for 
normalization of samples, whereas the housekeeping gene hypoxanthine guanine phosphoribosyl 
transferase (HPRT), spanning over intron-exon borders, served as control for RNA purity.  
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2.3.3 Quantitative real time-PCR analysis 
Quantitative real-time PCR (qRT-PCR) analysis of COX subunit IV isoforms was performed 
using SYBR® Green technology and carried out on the iQ5 detection system (Bio-Rad). The 
ability to monitor the real-time progress of the PCR completely supported the way of PCR-based 
quantification of DNA and RNA. Reactions are characterized by the point in time during cycling 
when amplification of a PCR product is first detected rather than the amount of PCR product 
accumulated after a fixed number of cycles. The higher the starting copy number of the nucleic 
acid target, the sooner a significant increase (above base line) in fluorescence is observed. In the 
initial cycles of PCR, there is only little change in fluorescence signal. This defines the baseline 
for the amplification plot. A fixed threshold is set above this baseline. An increase in 
fluorescence above the threshold indicates the detection of accumulated PCR product. The 
parameter “Ct” (threshold cycle) is defined as the fractional cycle number at which the 
fluorescence passes the fixed threshold. Quantification of the amount of target in unknown 
samples is accomplished by measuring Ct and using the standard curve to determine starting copy 
number. Forward and reverse primers for specific amplification of target genes (see the table 2.3) 
were designed eliminating the possibility of amplifying genomic DNA. For each set of primers, a 
basic local alignment search tool (BLAST, NCBI) search was used which revealed that sequence 
homology was obtained specifically for the target gene. Standard and sample cDNA obtained 
after reverse transcription were diluted 1:10 and added to a solution containing 5 µM primers and 
IQ SYBR Green Supermix (Bio-Rad, Munich, Germany) consisting of 25 U/ml iTaq polymerase, 
50 mM KCl, 20 mM Tris-HCl, 0.2 mM each dNTP, 3 mM MgCl2, SYBR Green I and stabilizers. 
The RT-PCR protocol was composed of an initial denaturation step for 3 min at 95°C followed 
by 40 cycles consisting of 10 s at 95°C, 30 s at the appropriate for the target gene annealing 
temperature (60°C – COX IV-1, 18S rRNA; 65°C – COX IV-2; 61°C – HPRT), 30 s at 72°C, and 
10 s at 78°C. To obtain melting curves for the resulting PCR products, a final step was added to 
the RT-PCR consisting of 81 cycles of increasing temperature from 55°C to 81°C by 0.5°C for 10 
s each step. Here, the PCR products were quantified using the relative ΔCt method. Relative 
quantification relates the PCR signal of the target transcript to that of 18S rRNA in treated with 
respect to untreated cells. A test for an approximately equal efficiency of target amplification was 
performed by looking at ΔCt value variations with template dilutions. 18S rRNA and Hprt served 
as endogenous control in the validation experiments. The absolute value of the slope of log input 
amounts versus ΔCt should be approximately -3.3 and the efficiency approximately 100%. The 
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validation experiments passed this test. The results are expressed as an average of triplicate 
samples of at least three independent experiments for control and treated cells. 
 
 
Table 2.3: Primers used for polymerase chain reaction 
 
 
Gene name  Forward Primer (5’-3’) 
Reverse Primer (5’-3’) 
Product 
size (bp) 
Gene bank  
accession no. 
18S rRNA CGG CTA CCA CAT CCA AGG AA 
GCT GGA ATT ACC GCG GCT 
186 X00686 
COX IV-1 TAT GCT TTC CCC ACT TAC GC 
GCC CAC AAC TGT CTT CCA TT 
219 NM_009941 
COX IV-2 AGA TGA ACC ATC GCT CCA AC 
ATG GGG TTG CTC TTC ATG TC 
184 NM_053091 
Hprt GCT GGT GAA  AAG  GAC CTC T 
CAC AGG ACT AGA ACA CCT GC 
228 NC_000086.6 
                          
2.4 Colorimetric, fluorometric and luminometric assays  
2.4.1   Intracellular ATP determination 
The intracellular ATP content of astrocytes and neurons were determined using the ATP 
Bioluminescence Assay Kit HS II (Roche) which was based on the following principle. The 
luciferase from Photinus pyralis (American firefly) catalyses the following reaction: 
 
ATP + D-luciferin + O2 → oxyluciferin + PPi + AMP + CO2 + light 
The resulting green light has an emission maximum at 562 nm. 
 
NPA-treated and untreated control cells were washed with ice-cold 1X PBS, scraped and re-
suspended in an equal amount of cell lysis reagent and dilution buffer. All these processes were 
carried out on ice. Obtained solution was centrifuged for 5 min at 12 000 g at 4°C (Eppendorf 
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5417R) and supernatants were transferred into a microtiter plate (Dynex) and an equal amount of 
luciferase reagent was added. The luminescent reaction during absorbance/illumination at 562 nm 
was analyzed immediately in a microplate reader (Victor, 1420 Multilabel Counter). ATP 
concentrations were calculated using the standard curve. Standards were made of a serial dilution 
of ATP concentration ranging from 10-3 to 10-12. The ATP content of the NPA-treated cells was 
calculated with respect to untreated controls set as 100%.  
 
2.4.2 Hydrogen peroxide detection in mitochondria 
Peroxide generation in mitochondria was measured using Amplex Red Hydrogen 
Peroxide/Peroxidase Assay Kit (Invitrogen). The principal behind the use of this kit is as 
followed. In the presence of peroxidase, the Amplex Red reagent reacts with H2O2 in a 1:1 
stoichiometry to produce the red-fluorescent oxidation product, resorufin. Resorufin has 
absorption and fluorescence emission maxima of approximately 571 nm and 585 nm, 
respectively. This reaction has been used to detect as little as 10 picomoles of hydrogen peroxide. 
For the purpose of determining the mitochondrial peroxide production, freshly isolated 
mitochondria were resuspended in minimal volume of mitochondrial buffer and added to 100 µl 
Krebs-Ringer phosphate buffer comprised of 145 mM NaCl, 5.7 mM NaH2PO4, 4.86 mM KCl, 
0.54 mM CaCl2, 1.22 mM MgSO4, 5.5 mM glucose, pH 7.35, containing 50 µM Amplex Red 
reagent and 0.1 U/ml horseradish peroxidase. Quantification of hydrogen peroxide was done 
using a fluorescence microplate reader (Tecan GENios). Different H2O2 concentrations (0–3 µM) 
served as a standard to quantify sample H2O2 concentrations. Determination of protein in 
mitochondria was used for normalization. 
 
2.4.3 Measurement of reactive oxygen species (ROS)  
Cells were grown in 24-well plates at density of 5 x 104/well with or without treatment of NPA 
for 24 h in NBM and loaded with 5 µM H2DCF-DA (Molecular Probe, Eugene, OR) diluted in 
Dimethyl sulfoxide (DMSO). Cells were incubated for 45 min at 37°C. H2DCF-DA is permeable 
to the cells and can be hydrolyzed and acetate groups are removed by intracellular esterase which 
causes the oxidation within the cell. The esterase cleavage of the lipophilic blocking groups gives 
a charged form of 2',7'-dichlorofluorescin (DCFH) which is highly fluorescent product, 2',7'-
dichlorofluorescein (DCF) and can be retained by the cells in much better way. The intensity of 
DCF fluorescence was determined in triple using a fluorescence microplate reader (Tecan 
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GENios) with an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The 
background fluorescence intensity in the control wells without H2DCF-DA was subtracted in all 
cases. Fluorescence intensities were normalized against percentage of viable cells obtained from 
trypan blue method compared to control set as 1. 
 
2.4.4   Glycogen assay 
The glycogen content of astrocytes was determined using Glycogen Assay Kit (BioVision, 
Mountain View, CA, USA) accordingly to manufacturer’s instructions. In brief, NPA-treated and 
untreated control cells were homogenized with distilled water on ice and subsequently boiled for 
5 min to inactivate enzymes. After centrifugation of boiled samples at 12,000 g for 5 min to 
remove insoluble cell components, supernatants were taken and supplemented with Hydrolysis 
Enzyme Mix, Development Enzyme Mix, and OxiRed probe provided with the kit. The 
colorimetric measurement was performed in a microplate reader (Tecan GENios) by detecting the 
adsorbance at 570 nm. The glycogen content was calculated using glycogen standards with 
respect to controls (set as 100%). Determination of protein content was used for normalization. 
 
2.4.5 Protein determination 
The protein content of isolated mitochondria was determined by applying the BCATM Protein 
Assay Kit (Pierce). This method combines the reduction of Cu+2 to Cu+1 by protein in an alkaline 
medium (the biuret reaction) with the highly sensitive and selective colorimetric detection of the 
copper cation (Cu+1) using a unique reagent containing bicinchoninic acid. The purple-colored 
reaction product of this assay is formed by the chelation of two molecules of BCA with one 
copper ion. The water-soluble complex exhibits a strong absorbance at 562 nm that is nearly 
linear with increasing protein concentrations. Samples of frozen mitochondria were solubilized in 
mitochondrial buffer, centrifuged at 12 000 g for 5 min at 4°C (Eppendorf 5417R), and the 
resulting supernatant was used for the protein assay. BSA served as standard in the range of 
2,000 µg-25 µg. 
 
2.5 Mitochondria isolation and enzyme kinetics measurement 
2.5.1 Preparation of mitochondria from primary astrocytes 
Cells from culture dishes (about 3x107 astrocytes) were trypsinized and collected in 
mitochondrial buffer composed of 0.25 M sucrose, 10 mM Tris-HCl, 0.2 mM EDTA, 10 mM 
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NaF, and 10 mM theophylline, pH 7.8. Cells were ruptured by applying a shock-freeze and thaw 
treatment. Digitonin (0.1 mg/ml) and triethanolamine at a final concentration of 10 mM were 
added to the cell suspension and incubated for 10 min on ice. Solubilized cells were homogenized 
in a pre-cooled glass vessel with a pestle (Eppendorf) rotating manually and subsequently 
centrifuged at 300 g for 10 min at 4°C (Eppendorf 5403). The resulting supernatant was 
transferred into a tube, while the pellet was re-suspended in mitochondrial buffer for another 
cycle of centrifugation at 300 g for 10 min at 4°C. Supernatants were pooled together and 
centrifuged at 12,000 g for 15 min at 4°C (Eppendorf 5417). The final pellet containing 
mitochondria was re-suspended in mitochondrial buffer including 1 mM phenylmethansulfonyl 
fluoride to prevent proteolysis. Mitochondria were shock-frozen and aliquots were stored at -
20°C until measurement. 
 
2.5.2 Polarographic measurements 
Mitochondria isolated from non-treated control and NPA-treated striatal astrocytes were thawed 
and kept on ice throughout polarographic measurements as suggested in Horvat and Arnold, 
2006.  To assess cytochrome c oxidase activity, mitochondria were re-suspended and solubilized 
in a buffer containing 50 mM KH2PO4, 1% (v/v) Tween® 80, pH 7.4 including 12 mM ascorbate, 
and either 5 mM ADP or 5 mM ATP, 1 mM phosphoenolpyruvate, 5 mM MgCl2 (Roth), and 5 
units pyruvate kinase at increasing concentrations (0-80 µM) of bovine heart cytochrome c 
(Fluka). The COX activity was measured using an Oxygraph system (Helmut Saur Laborbedarf, 
Reutlingen, Germany) and is given as turnover number (TN; consumed O2 [µM] / (time [s] x 
total amount of protein [mg])). Maximal enzyme activity (vmax) was determined at 50 µM 
cytochrome c, and the Michaelis-Menten constant (Km) was calculated for COX kinetics in the 
presence of ADP or ATP including an ATP regenerating system using Lineweaver-Burk plots 
using the software Graphpad PRISM5. The Hill coefficient was calculated from the slope of plots 
of log v/(vmax – v) against log cytochrome c concentration ([µM]). 
 
2.6 Statistical Analysis  
Data are presented as means ± SEM of at least three independent experiments. For statistical 
analysis, data were analyzed by applying ANOVA followed by a posthoc two-tailed, independent 
Student’s t test applying the software SPSS (Chicago, IL, USA). Values were regarded as 
statistically significant at *** p< 0.001, ** p < 0.01, * p < 0.05. 
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3.    Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic   
        acid-induced toxicity in striatal astrocytes 
 
3.1 Abstract 
Astrocyte mitochondria play an important role for energy supply and neuronal survival in the 
brain. Toxic and degenerative processes are largely associated with mitochondrial dysfunction. I, 
investigated the effect of 3-nitropropionic acid (NPA), a mitochondrial toxin and in vitro model 
of Huntington’s disease (HD), on mitochondrial function and viability of primary striatal 
astrocytes. Although NPA is known as an irreversible inhibitor of succinate dehydrogenase, I 
observed an increase of astrocyte ATP levels after NPA treatment. This effect could be explained 
by NPA-mediated alterations of cytochrome c oxidase subunit IV isoform (COX IV) expression. 
The up-regulation of COX isoform IV-2 caused an increased enzyme activity at the expense of 
elevated mitochondrial peroxide production causing increased cell death. The application of a 
small interfering RNA against COX IV-2 revealed the causal implication of COX isoform IV-2 
in NPA-mediated elevation of oxidative stress and necrotic cell death. Thus, I propose a novel 
additional mechanism of NPA-induced cell stress and death which is based on structural and 
functional changes of astrocyte COX and could indirectly impair neuronal survival. 
 
3.2 Introduction 
There is a growing body of evidence that mitochondria play a crucial role in toxic and 
neurodegenerative processes (Ayla et al. 2007; Beal, 2005). Several mitochondrial toxins, such as 
3-nitropropionic acid (NPA), are used as in vitro and in vivo models of neurodegeneration. 
Chronic and systemic administration of NPA as an irreversible inhibitor of succinate 
dehydrogenase (SDH) to rodents or primates causes a selective loss of medium spiny neurons in 
the striatum (Brouillet et al. 1999; Vis et al. 1999). The respective pathology and symptoms are 
similar to those observed in Huntington’s disease (HD). HD is a hereditary neurodegenerative 
disorder characterized by motor and cognitive deficits. These symptoms are associated with a 
progressive degeneration of GABAergic neurones in the striatum and the deep layers of the 
cerebral cortex (de la Monte et al. 1988; Ferrante et al. 1987). Although the mechanisms leading 
to neurodegeneration are unknown, compelling evidence indicates that mitochondrial dysfunction 
occurs quite early in the course of HD and can be observed in transgenic models of the disorder 
(Jenkins et al. 1998; Koroshetz et al. 1997; Panov et al. 2002; Sawa et al. 1999). Thus, 
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neurodegeneration could result from an impairment of oxidative energy metabolism and 
subsequent indirect excitotoxic neuronal damage (Beal, 2005; Brouillet et al. 1999). The primary 
mechanism underlying NPA-induced striatal toxicity is apparently a selective downregulation of 
protein expression and inhibition of the activity of respiratory chain complex SDH which is 
consistently found to be reduced in the striatum of patients with HD (Browne et al. 1997; Gu et 
al. 1996; Tabrizi et al. 1999). Astrocytes are the predominant cell type in the brain supporting 
neuronal viability and function (Jourdain et al. 2007; Pellerin et al. 2007). Among other 
important functions, astrocytes provide for and regulate energy homeostasis under normal 
conditions but appear to be particularly involved in the modulation of energy metabolism under 
pathological conditions in the central nervous system (de Keyser et al. 2008; Giaume et al. 2007). 
To figure out the contribution of astrocytes for neuronal vulnerability against NPA and in HD, I 
studied the effect of NPA on mitochondrial energy production in primary astrocytes cultured 
from mouse brain striatum. Despite the fact, that NPA primarily affects complex II of the 
respiratory chain, I investigated the terminal enzyme of the respiratory chain, cytochrome c 
oxidase (COX). COX is a complex enzyme consisting of 13 subunits, three of which are encoded 
by the mitochondria genome and fulfil the catalytic function, whereas ten additional nuclear-
encoded subunits provide a regulatory potential to the enzyme (Grossman and Lomax, 1997; 
Kadenbach et al. 2000). One of the regulatory COX subunits (COX IV) occurs in two isoforms, 
i.e. COX IV-1 and IV-2 (Hüttemann et al. 2001). The expression of COX subunit IV-1 isoform 
renders the enzyme sensitive towards the cellular energy level and enables it to couple the rate of 
ATP production to energetic requirements. The underlying mechanism of this regulatory process 
involves the binding of ATP to subunit IV-1 in the presence of a high ATP/ADP ratio, thereby 
causing an allosteric inhibition of COX (Arnold and Kadenbach, 1997; 1999; Horvat et al. 2006). 
Expression of COX isoform IV-2, however, prevents this regulatory mechanism (Horvat et al. 
2006). With respect to the potential role of COX in stress-induced apoptosis and degenerative 
diseases, I aimed to analyze the COX subunit IV isoform expression and the related functional 
consequences on survival of striatal astrocytes after NPA treatment (Kadenbach et al. 2004). 
 
3.3 Methods and material 
3.3.1   Primary striatal astrocytes culture  
Primary astrocytes were prepared from BALB/c mice on postnatal day 1 as described in 2.1.1. 
Before reaching confluence, astrocytes were trypsinized and plated at lower density. Sub-
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confluent astrocytes were incubated in neurobasal medium (NBM) for 48 hours and subsequently 
used for experiments. 
 
3.3.2   Cell treatment  
Primary neurons placed on culture dishes at 37°C in a humidified atmosphere were treated in the 
presence of different concentrations (1 µM-25 mM) of 3-nitropropionic acid (NPA; Sigma-
Aldrich) in NBM supplemented with 0.4% (v/v) B27, 50 U/ml penicillin, 50 μg/ml streptomycin, 
2 mM L-glutamine (Glutamax®) for the time interval indicated. Cells of the same preparation 
maintained under the same conditions except for NPA served as controls. 
 
3.3.3   Transfection and small interference (siRNA)-mediated knock-down  
Gene-silencing approach, using small interference RNA (siRNA) was used to knock-down the 
COX IV-2 gene. To achieve successful knock-down, treated and un-treated striatal astrocytes 
were transfected with optimized siRNA against COX IV-2 (5’-
GCGAGUCUAUGUGUUCCCUtt-3’) as mentioned in section 2.1.3. 
 
3.3.4   Immunocytochemistry  
To verify the purity of astrocytic culture, immunocytochemistry was performed with astrocytic 
marker. Cells grown on PLO coated coverslips were stained with Hoechst and passed through the 
steps described in section 2.2.1. Primary antibody against glial fibrillary acidic protein (GFAP, 
Encor, Gainsville, FL, USA), a specific marker for astrocytes was added to cells. To view the 
presence of GFAP within the cells secondary antibody Alexa Fluor® 488 labelled donkey anti-
mouse IgG (Invitrogen, Göttingen, Germany) was used. 
 
3.3.5   Cell viability, apoptosis, and necrosis assays  
Cell viability was determined applying the exclusion and Hoechst staining Trypan Blue methods 
as described in section 2.2.2 and 2.2.3 respectively.  Cell viability was presented as percentage of 
the ratio of unstained (viable) cells to the total number of cells (stained and unstained cells). Cells 
were counted from three distinct areas (3x10
5 
μm
2 
per field) of three independent cell 
preparations. Viability of control cells was referred to as 100%. To distinguish between apoptotic 
and necrotic astrocytes, Hoechst and propidium iodide staining was performed as described in 
section 2.2.2. 
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3.3.6   Reverse transcription and Real time PCR 
Total RNA was isolated using PEQGOLD, reverse transcribed. cDNA was amplified and 
analyzed for starting amount as described in section 2.3. For the relative quantification of the 
COX IV-1 and COX IV-2 in un-treated and NPA treated primary striatal astrocytic culture, real 
time PCR was performed using SYBR-Green mix (Bio-Rad). 18S rRNA and Hprt were 
employed as normalizing genes. The identity of PCR products was confirmed with melting curve 
analyisis and agarose gel electrophoresis. 
 
3.3.7   ATP assay  
Intracellular ATP content of cultured cells was determined using the ATP Bioluminescence 
Assay Kit HS II (Roche, Mannheim, Germany) according to manufacturer´s instructions. Details 
have been provided in section 2.4.1. The ATP content of NPA-treated cells was calculated and 
normalized to the number of viable cells with respect to un-treated controls set as 100%.  
 
3.3.8   Glycogen assay 
Glycogen content of astrocytes was determined using Glycogen Assay Kit (BioVision, Mountain 
View, CA, USA) accordingly to manufacturer’s instructions. The colorimetric measurement was 
performed in a microplate reader (Tecan GENios) by detecting the absorbance at 570 nm. The 
glycogen content was calculated by using glycogen standard and with respect to untreated 
controls set as 100%. Determination of protein content was used for normalization. 
 
3.3.9   Mitochondrial isolation and polarographic measurements  
Mitochondria were isolated from treated and un-treated striatal astrocytes and frozen in -80 
degree as suggested in section 2.5.1. Thawed aliquots of frozen isolated mitochonbdria served as 
samples for polarographic measurements to determine COX kinetics (Maximal enzyme activity 
(vmax) and the Michaelis-Menten constant (Km) in the presence of ADP or ATP including an 
ATP regenerating system. The detailed process for polarographic measurement has been 
mentioned in section 2.5.2. 
 
3.3.10   Hydrogen peroxide detection in mitochondria 
Peroxide generation in mitochondria was measured using Amplex Red Hydrogen 
Peroxide/Peroxidase Assay Kit (Invitrogen). Mitochondria were isolated as described in section 
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2.5.1. The isolation needed to be fast and on cold temperature throughout (on ice). The isolated 
mitochondria were instantaneously measured for peroxide production as described in 2.4.2.  
 
3.4 Results 
3.4.1   Treatment of striatal astrocytes with NPA causes an impairment of cell viability. 
Isolated primary astrocytes from mouse brain striatum (postnatal day 1) showed mainly GFAP-
immunoreactive cells (> 95%) and were virtually free of neurons, oligodendrocytes, and 
microglial cells (Fig. 3D). 
 
                                                                                              
A
100 µm 100 µm 
100 µm     100 µm 
 B
C D
Fig. 3 Immunocytochemical staining of primary striatal astrocytes striatal astrocytes in culture are 
shown under phase-contrast microscope (A) Nuclei were visulized after Hoechst staining (B). 
Immunocytochemical staining was performed with a primary antibody against GFAP and alexa Fluor 488 
conjugated secondary antibody (C) Co-staining of Hoechst and GFAP confirmed the purity of astrocytic 
culture.  
 
To assess the role of mitochondria in toxic processes, cultured astrocytes were treated with the 
NPA in a time and concentration-dependent way. A high rate of cell death was observed, when 
cells were treated with 10 mM NPA for 48 h (Fig. 4B/C). Staining of striatal astrocytes with 
Trypan Blue and Hoechst revealed approximately 10% cell death in the astroglial cell population 
under normal culturing conditions, whereas treatment of cells with 10 mM NPA caused an 
elevation of cell death up to 30% after 48 h (Fig. 4A). Applying different methods for identifying 
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necrotic and apoptotic cell death, i.e. staining of cells with Trypan Blue (Fig. 4A), Hoechst (Fig. 
4A/B/C), and propidium iodide, similar results were obtained.    
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Fig. 4 Viability of primary striatal astrocytes is impaired after NPA treatment. (A) The percentage of 
viable primary striatal astrocytes was decreased after 24 and 48 h treatment with 10 mM NPA when 
compared to untreated astrocytes. Viability was assessed by staining astrocytes with Trypan Blue (white 
columns) and Hoechst 33342 (black columns). The number of untreated and treated viable cells was 
counted and expressed as % of total cell number undergoing the experiment. (B/C) Hoechst-stained 
astrocytes were analyzed for apoptosis (grey columns) and necrosis (black columns). Both, apoptosis and 
necrosis, were increased after NPA treatment with necrosis showing a higher percentage of cell death. 
Data represent mean ± SEM (*p<0.05, **p<0.01, N=8). 
 
Cell treatment for 24 h or longer showed no difference in the rate of cell death (Fig. 4A/B), 
whereas NPA at a concentration higher than 10 mM caused a significant increase of apoptotic but 
no further significant elevation of necrotic cell death rates (Fig. 4C). For the following studies, a 
concentration of 10 mM NPA was applied for 48h. Necrotic cell death occurred in NPA-treated 
astrocyte cultures to a higher degree than apoptosis as determined by staining cells with Hoechst 
and propidium iodide (Fig. 4B/C). Approximately 20% of astrocytes were undergoing necrotic 
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cell death, whereas ca. 8% of cells were dying from apoptosis. Under control conditions, necrosis 
was slightly more pronounced than apoptosis. 
 
3.4.2   COX subunit IV isoform transcription and enzyme kinetics are affected by NPA.  
To study the effect of NPA on structural and functional aspects of the terminal mitochondrial 
respiratory chain enzyme, COX subunit IV isoform transcription was analyzed in astrocytes 
untreated and treated for 48 h with 10 mM NPA (Fig. 5A-C) and with NPA at different 
concentrations (Fig.5D/E). Quantitative real time-PCR (qRT-PCR) analysis revealed a higher 
basal transcription level of COX IV-1 in comparison to COX IV-2 under normal conditions, 
whereas significant changes in the transcription of COX isoforms IV-1 and IV-2 occurred after 
10 mM or 25 mM NPA for 48 h (Fig. 5A/B, D/E). COX IV-1 transcription after 10 mM NPA for 
48 h was decreased by approx. 50% and an 4-fold increase was seen for COX IV-2 (Fig. 5A/B). 
However, neither the treatment of astrocytes with 10 mM NPA for 1 h with a subsequent 
incubation period under control conditions for further 47 h nor an incubation time shorter than 24 
h in the presence of NPA at concentrations lower than 10 mM were sufficient to induce 
significant changes in the transcription levels of COX subunit IV isoforms. The antidromic 
change in COX IV isoform transcription after 48 h of NPA exposure led to an approx. 8-fold 
increase of the COX IV-2/COX IV-1 ratio (Fig. 5C). The various concentrations of NPA 
treatment showed similar results as obtained for NPA-induced changes of astrocyte viability 
which evokes that COX subunit IV isoform transcription reached highest levels after 48 h of cell 
treatment with 10 mM or 25 mM NPA.                   
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Fig. 5 NPA induced an up-regulation of COX IV-2 transcripts and a down-regulation of 
COX IV-1 transcripts. COX IV-1 and IV-2 transcript levels were quantified by qRT-PCR after treatment 
of striatal astrocytes for 48 h with 10 mM NPA (A-C) and at different NPA concentrations (D/E). 
Transcription levels were normalized to 18S rRNA and compared with untreated control cells (*p<0.05, 
**p<0.01, ***p<0.001, N=5). (A) NPA treatment showed a maximal decrease of COX IV-1 transcription 
form 1.4 to 0.7 after 48 h NPA treatment, whereas (B) COX IV-2 transcription reached maximal increase 
from 0.4 to 1.5 after 48 h of NPA treatment. (C) COX IV-2/COX IV-1 ratio showed a 7.5-fold increase 
after 48 h treatment of cells with NPA compared with the isoform ratio in untreated control cells set 1. 
(D/E) Treatment of astrocytes with NPA at concentrations of 10 mM and 25 mM caused maximal 
decrease of COX IV-1 (D) and maximal increase of COX IV-2 transcription (E). 
 
As previously shown for astrocyte COX regulation under hypoxia, changes in the COX subunit 
IV isoform expression pattern caused significant alterations in the kinetic parameters of COX 
(Horvat et al., 2006). Therefore, mitochondria isolated from treated and untreated astrocytes were 
solubilised and COX activity was assessed. To mimic COX activity at a high cellular energy 
level, oxygen consumption of solubilised mitochondria was measured in the presence of 5 mM 
adenosine 5’-triphosphate (ATP), whereas a low cellular energy level was mimicked by addition 
of 5 mM adenosine 5’-diphosphate (ADP). COX from untreated astrocytes showed a hyperbolic 
curve of the enzyme turnover numbers (TN) in dependence on cytochrome c concentrations and 
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in the presence of ADP, whereas a sigmoid curve was presented in the presence of ATP (Fig. 
6A/B). This reflects the allosteric inhibition of COX by ATP at high energy levels, i.e. at 
physiological cytochrome c concentrations of 2 µM (van Beek-Harmsen and van der Laarse, 
2005). COX activity was inhibited. 
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Fig. 6 Treatment of astrocytes with NPA induced a change of the COX kinetics characteristics of 
COX. (A, B) Ascorbate-stimulated COX activity of solubilized mitochondria isolated from striatal 
astrocytes treated with 10 mM NPA for 48 h (grey symbols and lines) and from untreated control cells 
(black symbols and lines) was measured polarographically at increasing concentrations of cytochrome c 
(N=8). COX activity was measured in the presence of 5 mM ATP (squares) and 5 mM ADP (circles). 
Data are given as TN (consumed O2 [IM]/total protein [mg] x s). (B) represents an insert of (A) to better 
visualize the allosteric inhibition of COX at physiologically relevant cytochrome c concentrations 
 
The allosteric feature of COX inhibition by ATP is further substantiated by a Hill coefficient of 
1.9 in the presence of ATP (Fig. 7C). With decreasing ATP/ADP ratios I observed a decrease of 
the Hill coefficient down to approximately 1.28 in the presence of ADP. Furthermore, the 
maximal TN of COX (vmax) at the highest substrate concentration of 50 µM cytochrome c was 
decreased in the presence of ATP by approximately 50% when compared to ADP-stimulated 
respiration (Fig. 6A, 7A). The Michaelis-Menten constant (Km) of COX for cytochrome c was 
approximately 4-fold lower in the presence of ADP than in the presence of ATP (Fig. 7B). These 
kinetic COX characteristics were significantly changed after treatment of striatal astrocytes with 
10 mM NPA for 48 h NPA-treated astrocytes exhibited an overall increase in COX activity 
independently of the ATP/ADP ratio (Fig. 7A). In the presence of ADP, vmax of COX was 
increased by 28%, whereas it was elevated by 50% in the presence of ATP. This was 
accompanied by a 25% and 20% increase of the Km of COX for cytochrome c in the presence of 
ATP and ADP, respectively (Fig. 7B). Whereas the Hill coefficient remained unchanged for 
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COX of untreated vs. treated astrocytes in the presence of ADP, I observed a significant decrease 
in the presence of ATP from 1.9 to 1.4 (Fig. 7C). This is equivalent to an abolition of the 
allosteric COX inhibition in the presence of high ATP/ADP ratios.  
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Fig.7 Treatment of astrocytes with NPA caused changes of the kinetic characteristics of COX. 
Ascorbate-stimulated COX activity of solubilized mitochondria from striatal astrocytes treated with 10 
mM NPA for 48 h (NPA) and from untreated control cells (Control) were measured polarographically in 
the presence of ADP (grey columns) and ATP (black columns) as described in Fig. 3. (A) Maximal 
turnover numbers are presented. Data are given as TN (consumed O2 [IM]/total protein [mg] x s) at 50 IM 
cytochrome c. (B) The Michaelis–Menten constant and (C) the Hill coefficient were calculated for COX 
kinetics. Data are presented as mean ± SEM (*p<0.05, **p<0.01, NPA-treated samples vs. 
untreatedcontrols; #p<0.05, ##p<0.01, kinetic characteristics measured in the presence of ADP  vs. ATP; 
N=8) 
 
3.4.3   NPA-induced increases of COX activity was accompanied by elevated intracellular 
ATP levels at the expense of a higher peroxide production. 
Furthermore, I studied the effect of NPA on the intracellular energy level by measuring the ATP 
level. Treatment of astrocytes with NPA at concentrations of 10 mM or higher and for 24 or 48 h 
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caused an elevation of ATP in viable cells by approximately 20% (Fig. 8A/B). This increase in 
ATP was paralleled by an approximately 7-fold elevation of mitochondrial peroxide production 
(Fig. 8C). Additionally, the glycogen content of astrocytes was measured after NPA treatment to 
evaluate the metabolic status of astrocytes. An insignificant decrease of glycogen by 
approximately 7% was detected (data not shown).  
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Fig. 8 Intracellular levels of ATP and mitochondrial peroxide production were elevated after NPA 
treatment of astrocytes. (A/B) The intracellular ATP levels measured by applying an ATP 
bioluminescence assay kit were increased by ca. 20% after 24 and 48 h of NPA treatment of primary 
striatal astrocytes (A) at a concentration of 10 mM and 25 mM (B). (C) Mitochondrial peroxide 
production detected as a measure of reactive oxygen species in astrocytes was 7-fold increased upon 10 
mM NPA treatment for 48 h. Data were compared to untreated control samples set 100% (dotted lines; 
*p<0.05, ***p<0.001, N=4) 
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3.4.4  Elevated COX isoform IV-2 transcription is causally correlated with elevated 
oxidative stress and necrotic cell death of NPA-treated striatal astrocytes. 
In order to reveal that elevated COX IV-2 transcript levels in astrocytes treated with 10 mM NPA 
for 48 h are causally linked to the observed changes in the ATP and peroxide production as well 
as cell viability, a small interfering RNA (siRNA) approach against COX IV-2 was applied. In a 
first attempt, the efficiency of the siRNA application was scrutinized by qRT-PCR revealing a 
down-regulation of COX IV-2 transcript levels from approximately 400% after NPA treatment to 
ca. 40% when striatal astrocytes were treated with siRNA against COX IV-2 for 24 h prior to 
NPA exposure for 48 h (Fig. 9B). The application of siRNA against COX IV-2 did not exert any 
significant effects on the down-regulated COX IV-1 transcription levels detected after NPA 
treatment (Fig. 9A). Treatment of astrocytes with scrambled siRNA as a negative control caused 
only marginal changes in COX IV-1 or IV-2 transcription.  
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Fig. 9 Application of siRNA against COX subunit isoform IV-2 showed a knock-down of this 
isoform in NPA-treated astrocytes. COX IV-1 (A) and COX IV-2 (B) transcription levels were 
quantified by qRT-PCR after treatment of striatal astrocytes with 10 mM NPA for 48 h in the absence 
(NPA) and presence of siRNA against COXIV-2 (NPA+siIV-2) and compared to untreated control 
samples (control; **p<0.01, N=5). Applying siRNA against COX IV-2 to NPA-treated astrocytes caused a 
down-regulation of COX IV-2 below basal transcription level in untreated control cells, whereas no 
changes in COX IV-1 transcription were observed. 
 
Subsequently, I assessed the intracellular ATP levels and mitochondrial peroxide production (Fig. 
7A and B, respectively). The knock-down of COX IV-2 led to a decrease of NPA-induced 
intracellular ATP elevation from 117% to 107% (Fig. 10A). This was paralleled by a decrease of 
mitochondrial peroxide production from 700% to 400% after knock-down of COX IV-2 (Fig. 
10B). The down-regulation of elevated ATP and peroxide production was paralleled by a 
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decrease of necrotic cell death of NPA-treated striatal astrocytes by approximately 50% (Fig. 
10C) 
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Fig. 10 Knock-down of COX isoform IV-2 improved astrocyte survival during NPA treatment by 
diminishing ROS production. Astrocytes were assessed for (A) intracellular ATP, (B) peroxide 
production, and (C) Hoechst-stained necrotic cell death. Data are calculated as percentage of ATP (A) and 
peroxide production (B) in treated compared to untreated control cells set 100%. Necrotic cell numbers 
(C) are given as percentage of the total cell number. All data are presented as mean ± SEM (*p<0.05, 
**p<0.01, NPA-treated samples vs. untreated controls; #p<0.05, NPAand siRNA-treated samples vs. 
NPA-treated samples; N=5). Knock-down of COX IV-2 caused a down-regulation of ATP and peroxide 
production as well as necrotic cell death. 
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3.5 Discussion 
NPA-mediated toxicity resembles one of the toxin-induced models which have been generated in 
addition to transgenic and knock-in animal models to study the pathogenic mechanisms of 
Huntington’s disease (Ramaswamy et al. 2007). Despite the availability of these different 
models, it is still unclear as to why medium spiny striatal neurons selectively die in HD. One 
possible mechanism of cell death in mutant huntingtin transgenic and druginduced mouse models 
involves mitochondrial abnormalities of neurons (Browne et al. 1997; Gellerich et al. 2008; Gu et 
al. 1996; Schapira, 1997; Tabrizi et al. 1999). To mimic mitochondrial dysfunction, NPA is used 
both in vitro and in vivo to model acute insults such as ischemia as well as neurodegenerative 
disorders including Huntington’s and Alzheimer’s disease (Ayla et al. 2007; Beal, 2005; Geddes 
et al. 2000). Previous studies focused mainly on neurons, although it recently became more 
evident that astrocytes play a crucial role for neuronal survival under toxic and degenerative 
conditions (Kipp et al. 2006; Maragakis and Rothstein, 2006). Essential functions of astrocytes 
which are important in this context include the maintenance of the “neuronal milieu” including 
energy homeostasis (Barres, 1991). Neuronal loss can result from direct action of the toxin on 
neurons or indirectly through an involvement of astrocytes. In the absence of astrocytes, neurons 
are more prone to the effects of mitochondrial toxins and excitotoxic damage (Dugan et al. 1995). 
This indicates a crucial role for astrocytes in supporting neuronal function and survival. To 
examine the potential role of astrocyte mitochondria function in NPA-mediated neuronal toxicity 
and with respect to maximal effects obtained for cell death rate and COX subunit IV isoform 
transcription pattern, I applied 10 mM NPA for 48 h to cultured striatal astrocytes. I have chosen 
the striatum, since this brain region is most affected in HD. My findings of an increased cell 
death rate after NPA treatment is in agreement with the observation of a selective loss of striatal 
astrocytes after systemic application of NPA (Nishino et al. 1995). Preliminary experiments on 
NPA-treated astrocytes from cortex support the observations of a higher vulnerability of striatal 
in comparison with cortical astroglia providing additional mechanistic insights in a brain region-
specific role of COX and mitochondria in cell viability under toxic conditions (manuscript in 
preparation). I additionally provide evidence of a more pronounced necrotic than apoptotic death 
of striatal astrocytes. NPA as an inhibitor of succinate dehydrogenase (SDH), the complex II of 
the mitochondrial electron transport chain, is known to cause an impairment of mitochondrial 
energy production in neural cells (Ayla et al. 2007; Beal, 2005; Gu et al. 1996; Schapira, 1997). 
On the other hand, both necrosis and apoptosis are generally associated with impaired energy 
 
 
39
metabolism and could, therefore, explain the decreased survival of neural cells treated with NPA 
(Sawa et al. 2003). Indeed, an increased cell death after NPA treatment has been correlated with 
diminished energy production due to decreased respiratory chain enzyme activity (Beal, 2005; 
Sawa et al. 2003). Surprisingly, I observed elevated instead of decreased ATP levels. One 
explanation, why others reported an ATP decrease under similar conditions of treatment could be 
due to the normalization procedure of results on the ATP amount in cells in my study. ATP levels 
were correlated to the number of viable cells surviving the treatment rather than the total number 
of cells initially used for the experiment or the protein amount determined after NPA treatment 
which are used in other studies. An observation made by Esfandiari and colleagues demonstrating 
that SDH is only partially inhibited in astrocytes treated with 3 mM NPA for 4 h indicates that 
mitochondrial energy metabolism is not completely blocked by NPA and supports my data 
(Esfandiari et al. 1997). Taken into account that electrons enter the respiratory chain of 
mitochondria also at complex I, higher energy production can be assumed. Therefore, I suspected 
an involvement of COX, the terminal enzyme of the mitochondrial electron transport chain, and 
have analyzed the transcription pattern of COX subunit IV isoforms along with the kinetic 
characteristics of this enzyme. After NPA treatment, the enzyme exhibited an increased catalytic 
activity due to a switch in COX subunit IV isoforms from COX IV-1 to COX IV-2 in striatal 
astrocytes. Mechanistically, the changes of the catalytic properties of COX can be explained by 
an abolition of ATP/ADP binding to the N-terminus of COX subunit IV. COX is well known for 
its complex regulation by adenine nucleotides and hormones (Arnold and Kadenbach, 1997; 
1999; Arnold et al. 1998). An allosteric regulatory mechanism of COX activity has been 
demonstrated for COX isoform IV-1 at high energy levels in my earlier studies (Arnold and 
Kadenbach, 1997; 1999; Horvat et al. 2006).It indicates a crucial role for COX in sensing the 
cellular energy level and being able to couple it to mitochondrial ATP production (Horvat et al. 
2006). This mechanism is a specific feature of astrocyte COX but not occurring in neurons 
(Horvat et al. 2006). The reason for this may be a different COX IV isoform expression pattern in 
both brain cell types. The regulatory COX isoform IV-1 is expressed ubiquitously including 
astrocytes and neurons, but neurons do also reveal considerable COX IV-2 expression. 
Astrocytes only show marginal transcription of COX IV-2, an observation that holds true for 
astrocytes from different brain regions. Under hypoxic conditions, however, astrocytes 
demonstrate a significant induction of COX IV-2 transcription which is accompanied by an 
abolition of the allosteric COX inhibition by ATP (Horvat et al. 2006). In the present report, I 
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demonstrate a similar up-regulation of COX IV-2 paralleled by a down-regulation of COX IV-1 
transcripts after 48 h of NPA treatment of striatal astrocytes. This indicates that COX subunit IV 
isoform transcription is regulated also by toxic and not only by hypoxic stimuli. The NPA-
mediated increased COX IV-2 transcription was also accompanied by an abolishment of the 
allosteric inhibition of COX by ATP at high energy levels. This is supported by a decrease of the 
Hill coefficient, a measure of the cooperativeness of two substrate binding sites at the dimeric 
COX enzyme, from approximately 2 for COX in untreated astrocytes to approximately 1.5 in 
NPA-treated astrocytes. Thus, the enzyme is no longer able to detect the energy level and couple 
it to the ATP production. Irrespectively of the energy level (presence of ATP or ADP), astrocytic 
COX exhibited a higher catalytic activity (vmax) after NPA treatment of astrocytes than under 
normal cell culturing conditions. This could serve as an explanation for the observed rise of 
intracellular ATP. However, the switch from COX IV-1 to COX IV-2 transcription is, 
paradoxically, also accompanied by an increase in peroxide production which, in turn, explains 
the elevated necrotic cell death of striatal astrocytes after NPA treatment despite an increased 
cellular ATP level. Previously, I suggested that an abolition of the allosteric COX inhibition at 
high ATP/ADP levels could cause an increased production of reactive oxygen species (ROS) due 
to an elevated mitochondrial membrane potential (Lee et al. 2001). Thus, my finding of NPA-
mediated COX isoform IV-2 transcription, which prevents from the allosteric COX inhibition by 
ATP, supports the role for COX isoform IV-2 in oxidative stress. Generally, an increased COX 
activity is assumed to decrease the oxidative stress by decreasing the ROS production that is 
caused by a block of the electron transfer at complex III and I (Cadenas et al. 1977). However, 
recent reports suggest a role for an elevation of COX activity in ROS production (Dröse and 
Brandt, 2008). Thus, a higher COX electron transfer onto oxygen causes the ubiquinone pool to 
be oxidized to a higher degree, thereby enabling complex III to transfer electrons to oxygen and 
increase the oxygen radical production.To examine in more detail the metabolic status of 
mitochondria I measured the glycogen content. Although the astrocyte glycogen content was only 
marginally decreased after NPA treatment, this change could point at glycogen as a source for 
anaerobic ATP generation additionally to the utilization of exogenous glucose provided in the 
cell culture medium. Supportively, Dringen and colleagues (Wiesinger et al. 1997) considered 
glycogen in astrocytes as a store for generating lactic acid rather than glucose. This could serve as 
an additional factor for NPA-mediated increased ATP levels. Furthermore, NADPH regeneration 
by pentose phosphate pathway utilizing glycogen irrespective of exogenous glucose is essential 
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for the activity of the glutathione redox cycling (Rahman et al. 2000), a mechanism important for 
protecting cells from oxidative stress. An activation of this antioxidant pathway 
may explain the relatively limited cell death rate despite the high rate of mitochondrial ROS 
production. The impairment of mitochondrial energy production and increased ROS production 
are two pathways that are widely accepted mechanisms involved in neurodegeneration (Ayla et 
al. 2007; Beal, 2005). Here, I show that NPA treatment of striatal astrocytes did not increase cell 
death by a reduction of energy production rather by an increase in ROS production. The causal 
implication of COX isoform IV-2 was verified by the application of siRNA against COX IV-2. 
This attenuated the NPA-mediated increase of COX activity, ATP levels, and ROS production. 
My data highlight the crucial role for the COX isoform IV-2 in NPA-induced elevation of 
oxidative stress and necrotic cell death. This could affect proper astroglia function under 
pathological conditions and, in turn, indirectly impair neuronal survival. In my opinion, future 
studies of neurodegeneration should comprise local astroglia considering not only their basal 
supportive function for neurons but equally deciphering the action of toxins and pathological 
processes on this cell type. Stabilizing and improving astrocytic function may have a tremendous 
impact on neuronal survival in the brain. 
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4.   Brain region specificity of 3-nitropropionic acid-induced vulnerability of    
      neurons involves cytochrome c oxidase  
  
4.1 Abstract  
Mitochondria play a pivotal role in the regulation of energy metabolism and apoptotic pathways. 
Properties and functions of mitochondria might render subsets of selectively vulnerable neurons 
intrinsically susceptible to a different extent to cellular stress and degeneration. I investigated the 
effect of 3-nitropropionic acid (NPA), a mitochondrial toxin and in vitro model of Huntington’s 
disease, on mitochondrial function and viability of primary neurons isolated from mouse brain 
striatum and cortex. I observed a higher vulnerability of striatal compared with cortical neurons 
in response to NPA treatment. This effect could be correlated with the transcription pattern of 
cytochrome c oxidase (COX) subunit IV isoforms. In cortical neurons, NPA induced a down-
regulation of the COX IV-2/COX IV-1 ratio, whereas an up-regulation was found in striatal 
neurons. Previously, I have shown that an increased COX IV-2/COX IV-1 ratio is responsible for 
a higher enzyme activity which is paralleled by elevated intracellular ATP levels at the expense 
of increased mitochondrial peroxide production. These effects could also be demonstrated in 
striatal neurons. On the contrary, a decreased COX IV-2/COX IV-1 ratio was observed in cortical 
neurons, which was accompanied by a decrease in intracellular ATP content and no significant 
changes in mitochondrial peroxide production. I propose that COX isoform IV-2 mediates 
increased oxidative stress that is, at least in part, responsible for a higher vulnerability of striatal 
compared with cortical neurons against NPA. This mechanism, in turn, may serve as an 
explanation for brain region-specific differences in the neuronal susceptibility to toxic conditions.  
 
4.2 Introduction  
Huntington’s disease (HD) is a dominant inherited neurodegenerative disorder characterized by 
chorea as well as cognitive and psychiatric disturbances (The Huntington’s Disease Collaborative 
Research Group 1993). The progressively developing HD is reflected in an inexorable demise of 
neurons in the brain that is first manifest in the striatum (Martin and Gusella, 1986). Various 
disease mechanisms have been suggested including an expansion of the N-terminal CAG repeats 
of wild-type huntingtin, excitotoxic processes, oxidative stress, and an impairment of the cellular 
energy status due to mitochondrial dysfunction (Saulle et al. 2004; Beal 2005; Seong et al. 2005; 
Brouillet et al. 2005). There is a growing body of evidence that mitochondria play a crucial role 
in neurodegenerative and toxic processes (Beal 2005; Ayala et al. 2007). In line with this, 
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mitochondrial toxins are used as in vitro and in vivo models of neurodegeneration. For instance, 
chronic and systemic administration of NPA, an irreversible inhibitor of succinate dehydrogenase 
(SDH), causes a selective loss of medium spiny GABAergic neurons in the striatum of rodents 
and primates (Brouillet et al. 1999; Vis et al. 1999). The respective pathology and symptoms are 
similar to those observed in HD (Ferrante et al. 1987; de la Monte et al. 1988). Although the 
mechanisms leading to neurodegeneration are unknown, compelling evidence indicates that 
mitochondrial dysfunction occurs quite early in the course of HD and can be observed in 
transgenic and toxic models of the disorder (Koroshetz et al. 1997; Jenkins et al. 1998; Sawa et 
al. 1999; Panov et al. 2002). Data from post mortem tissues (caudate and putamen of the 
striatum) of HD patients suggest a selective down-regulation of protein expression and enzyme 
activities of mitochondrial respiratory chain complexes, especially SDH (Browne et al. 1997; Gu 
et al. 1996). Thus, neurodegeneration could result from an impairment of oxidative energy 
metabolism and subsequent neuronal damage (Brouillet et al. 1999; Beal 2005). However, NMR 
data from HD patients referring to in vivo ATP, lactate, creatine and phosphocreatine levels are 
conflicting with cortex exhibiting an earlier onset of hypometabolism than stiatum (Jenkins et al. 
1993; Sanchez-Pernaute et al. 1999; Hoang et al. 1998). To figure out the contribution of other 
components of the mitochondrial respiratory chain to brain region-specific differences of 
neuronal vulnerability towards NPA, I studied the effect of this neurotoxin on structural 
characteristics of cytochrome c oxidase (COX; E.C. 1.9.3.1.) and mitochondrial energy 
production in the context with the survival of primary neurons from mouse striatum and cortex. 
COX is a bigenomically expressed enzyme complex consisting of 13 subunits. One of the 
nuclear-encoded subunits COX IV enables the enzyme to be regulated (Grossman and Lomax 
1997; Kadenbach et al. 2000). This regulatory COX subunit IV occurs in two isoforms, i.e. COX 
IV-1 and IV-2 (Hüttemann et al. 2001). The expression of COX subunit IV-1 isoform renders the 
enzyme sensitive towards the cellular energy level and enables it to couple the rate of ATP 
production to energetic requirements. The underlying mechanism of this regulatory process 
involves the binding of ATP to subunit IV-1 in the presence of a high ATP/ADP ratio, thereby 
causing an allosteric inhibition of COX (Arnold and Kadenbach 1997; Arnold and Kadenbach 
1999; Horvat et al. 2006). Expression of COX isoform IV-2, however, prevents this regulatory 
mechanism (Horvat et al. 2006; Singh et al. 2008). With respect to the potential role of COX in 
stress-induced apoptosis and degenerative diseases, I particularly aimed to analyze the COX 
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subunit IV isoform expression and the related functional consequences on survival of striatal 
neurons after NPA treatment (Kadenbach et al. 2004). 
 
4.3 Methods and materials 
4.3.1   Primary neuronal culture  
Primary neurons were prepared from striatum and cortex of Balb/c mouse brains at gestation day 
16 and cultured as described previously in section 2.2. Preapred cortical and striatal neuronal 
cultures were maintained at 37°C in a humidified atmosphere of 95% air/5% CO
2
. After 24 h, the 
cell medium was deprived of FCS. This procedure typically yields >90% neurons.  
 
4.3.2   Cell treatment  
Primary neurons placed on culture dishes at 37°C in a humidified atmosphere were treated in the 
presence of 10 mM 3-nitropropionic acid (NPA; Sigma-Aldrich) in NBM supplemented with 
0.4% (v/v) B27, 50 U/ml penicillin, 50 μg/ml streptomycin, 2 mM L-glutamine (Glutamax®) for 
the time interval indicated. Cells of the same preparation maintained under the same conditions 
except for NPA served as controls. 
 
4.3.3   Immunocytochemistry  
The purity of primary neuronal cultures was determined by immunocytochemistry described in 
section 2.2.1. In particular, neuronal cultures were first stained in the presence of 2 μg Hoechst 
33342 Trihydrochlorid (Hoechst; Invitrogen) per ml for 10 min under culturing conditions. After 
washing with phosphate buffered saline (PBS, Gibco), the stained cells were fixed with 4% (w/v) 
paraformaldehyde (Merck) for 30 min at room temperature, washed twice with PBS, and 
permeabilized with PBS containing 0.2% (v/v) Triton X-100 (PBS-TX-100, Merck) for 15 min. 
Blocking was performed in the presence of 3% (w/v) BSA for 20 min at room temperature. 
Primary antibodies against neuronal nuclei (NeuN, Chemicon, Hofheim, Germany), pan-neuronal 
neurofilament (SMI 311, Covance, Emeryville, CA, USA), pan-axonal neurofilament (SMI 312, 
Covance), and glial fibrillary acidic protein (GFAP, Encor, Gainsville, FL, USA), a specific 
marker for astrocytes were added and incubated at 4°C overnight. Subsequently, cells were 
washed three times with PBS-TX-100 and incubated in the presence of secondary antibodies 
Alexa Fluor
® 
488 labelled donkey anti-mouse IgG (Invitrogen, Göttingen, Germany), cy3-
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conjugated goat anti-mouse IgG (Chemicon) or cy3-conjugated donkey anti-rabbit IgG (Jackson 
Immuno Research Laboratories/Dianova, Hamburg, Germany) diluted 1:500 or 1:400, 
respectively, for 2 h at room temperature. Cells were washed with PBS three times for 5 min and 
mounted with Mowiol (Fluka, Steinheim, Germany). Cells were examined using a fluorescence 
Axiovert 200M microscope (Carl Zeiss, Oberkochern, Germany) equipped with the software 
Axiovision 3.1 at excitation wavelengths of 365±12 nm (Hoechst), 450-490 nm (Alexa Fluor
® 
488) and 530-585 nm (cy3).  
 
4.3.4   Cell viability, apoptosis, and necrosis assays  
Cell viability was determined applying the exclusion and Hoechst staining Trypan Blue methods 
as described in section 2.2.2 and 2.2.4 respectively.  Cell viability was presented as percentage of 
the ratio of unstained (viable) cells to the total number of cells (stained and unstained cells). Cells 
were counted from three distinct areas (3x10
5 
μm
2 
per field) of three independent cell 
preparations. Viability of control cells was referred to as 100%. To distinguish between apoptotic 
and necrotic astrocytes, Hoechst and propidium iodide staining was performed as described in 
section 2.2.2. 
 
4.3.5   Reverse transcription and Real time PCR 
Total RNA was isolated using PEQGOLD, reverse transcribed and cDNA was amplified and 
analyzed for starting amount as described in section 2.3. For the relative quantification of the 
COX IV-1 and COX IV-2 in un-treated and NPA treated primary cortical and striatal neuronal 
culture, real time PCR was performed using SYBR-Green mix (Bio-Rad). 18S rRNA and Hprt 
were employed as normalizing genes. The identity of PCR products was confirmed with melting 
curve analyisis and agarose gel electrophoresis. 
 
4.3.6   ATP assay  
The intracellular ATP content of cultured neurons was determined using the ATP 
Bioluminescence Assay Kit HS II (Roche, Mannheim, Germany) according to the instructions of 
the manufacturer. Detailed process has been provided in section 2.4.1. The ATP content of NPA-
treated cells was calculated and normalized to the number of viable cells with respect to untreated 
controls set as 100%.  
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4.3.7   Measurement of intracellular production of reactive oxygen species  
ROS measurement was done as suggested in section 2.4.3. Primary neurons were cultured in 96-
well plates at a density of 5x10
4
cells/well. After treatment with or without NPA for 24 h, cells 
were loaded with 10 μM H
2
DCFDA diluted in PBS buffer and incubated for 45 min at 37°C. The 
fluorescence intensity of DCF after excitation of the samples at a wavelength of 485 nm was 
measured.  
 
4.3 Results 
 
4.3.1   Striatal neurons showed a higher vulnerability in response to NPA treatment than 
cortical neurons. 
Primary neuronal cultures from mouse brain striatum and cortex (gestation day 16) consisted of 
mainly NeuN-immunoreactive cells.  
            
Fig. 11 Immunocytochemical staining of primary neurons showed a ≥90% pure neuronal culture. 
The purity of primary cultures of striatal neurons (D, phase contrast) was analyzed after Hoechst-staining 
of cell nuclei (A) by immunocytochemical staining with NeuN (B) and GFAP (E) visualized after 
labelling with Alexa Fluor
® 
488 and cy3, respectively. Merged pictures of Hoechst-stained nuclei with 
NeuN- (C) or GFAP-immunostained cells (F) revealed highly purified neuronal cultures with astrocyte 
impurities to an extent of less than 10% (bars 100 μm).  
 
In Figure 11, representative striatal cultures labelled with Hoechst (Fig. 11A) and stained for 
NeuN (Fig. 11B) and/or GFAP (Fig. 11E) are presented. The majority of cells (≥ 90%) 
D 
A Hoechst B NeuN C  Merged: Hoechst + NeuN 
F  Merged: Hoechst + GFAP E GFAP 
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represented neurons (Fig. 11C), whereas non-neuronal elements including astrocytes stained for 
GFAP (Fig. 11F) were only marginally present.  
Neuronal cultures were treated with the mitochondrial toxin, NPA, in a time dependent manner 
with 10 mM NPA. Although  both 6 h ( Figs. 12 B, E) and 24 h ( Figs.12C, F) exposure of NPA 
to cells lead to viability loss,  highest numbers of dead cells were observed in striatum as well as 
in cortex after 24 h (Figs. 12C, F) of treatment with NPA at a concentration of 10 mM.                                          
                                         
 
 24 h 
Cortex + NPA Cortex + NPACortex 
 24 h 
Striatum + NPA Striatum + NPA
Control 
Striatum 
D E Control F6 h
B 6 h CA 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 
Fig. 12 Phase-contrast showed higher cell death of primary neurons in NPA (10 mM) treated cells 
for 24 h. 10 mM NPA treatment for 24 h caused a significant loss of viable cells in striatal (C) and 
cortical (D) cultures compared to the respective striatal (A) and cortical (C) controls and after 6h of NPA 
treatment (B, E), bars (100 µM) 
 
Staining of striatal and cortical neurons with neuron-specific antibodies (SMI 311 and SMI 312) 
showed morphological differences of neurons from these two brain regions. Cortical neurons 
exhibited a more pronounced net of processes than striatal neurons (Figs. 13C and A, 
respectively). Morphological changes in response to NPA treatment were not observed (Fig. 13). 
Exposure of both neuronal cultures to NPA for 24 h revealed a significant loss of viable cells. 
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A   BStriatum
Fig. 13 Immunocytochemical staining of primary neurons from mouse striatum (A, B) and cortex 
(C, D) after NPA treatment revealed a significant loss of viable cells. NPA treatment caused a decrease 
of the number of viable cells in striatal (B) and cortical (D) cultures compared to the respective striatal (A) 
and cortical (C) controls. Cells were immuno-labelled for neuronal and axonal neurofilament (SMI 311 
and SMI 312) and visualized by cy3-immuno-fluorescence (bars 100 μm).  
 
Trypan Blue and Hoechst staining showed similar neuronal cell death rates for cells from the 
same brain region, but revealed quantitative differences for neurons from striatum in comparison 
with cortex (14A, B). The number of viable cells in striatal neuronal cultures was significantly 
decreased after 24 h of NPA treatment (by approximately 40%), whereas cortical neurons showed 
a decrease in the number of viable cells to a lesser extent (by approximately 25%). Staining of 
untreated striatal neurons with Trypan Blue and Hoechst revealed neuronal death rates of 
approximately 10% under normal culturing conditions regardless of the brain region. More than 
24 h of treatment of NPA could not provoke higher cell death. To distinguish between apoptotic 
and necrotic cell death induced by NPA treatment, neuronal cultures were stained with Hoechst 
(14C, D) and propidium iodide. A predominance of neuronal necrosis became obvious in both 
brain regions after NPA treatment for 24 h (14C, D). Approximately 25% and 10% of cortical 
neurons were undergoing necrosis and apoptosis, respectively, whereas approximately 40% of 
striatal neurons followed necrotic and ca. 10% the apoptotic mode of cell death. Under control 
conditions, necrosis was also slightly more pronounced than apoptosis.  
C  DCortex
Striatum + NPA 
Cortex + NPA 
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Fig. 14 Striatal neurons showed a higher vulnerability to NPA than cortical neurons. The percentage 
of viable primary striatal (A,C) and cortical (B, D) neurons was decreased after 6h and 24 h treatment with 
10 mM NPA when compared to untreated cells. Viability was observed by staining neurons with Trypan 
Blue ((A/B, grey columns) and Hoechst 33342 (A/B, black columns). Hoechst and propidium iodide 
stained neurons were analyzed for apoptosis (grey columns) and necrosis (black columns) of striatal (C) 
and cortical neurons (D) and expressed as percentage of total cells counted in the experiments. Viability of 
control cells was referred to as 100%. Data represent means ± SEM (*p<0.05, **p<0.01, ***p<0.001, n = 
8).  
 
 
4.3.2   NPA induced an alteration in the COX subunit IV isoform transcription pattern 
To study the effect of NPA on structural properties of the terminal mitochondrial respiratory 
chain enzyme COX (E.C. 1.9.3.1.), I analyzed the transcription pattern of COX subunit IV 
isoforms in untreated and NPA-treated cultures. Quantitative real time-PCR (qRT-PCR) analysis 
revealed no significant differences between the basal transcription levels of COX IV-1 and COX 
IV-2 in striatal compared with cortical cells under control culturing conditions (Figs. 15A, B). 
After treatment with NPA for 24 h, significant changes of the COX isoform IV-1 and IV-2 
transcription occurred in a brain region-specific manner. COX IV-1 transcription was decreased 
in both, cortical and striatal, neurons by approximately 45%. COX isoform IV-2 transcript levels 
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demonstrated a two-fold elevation after NPA treatment in striatal neurons but a three-fold 
decrease in cortical neurons. Accordingly, the ratio of COX IV-2/COX IV-1 transcripts was 
reduced by 50% in cortical neurons and elevated three-fold in striatal neurons (Fig. 15C). 
   
A
Control NPA
0
1
2
##
**
C
O
X 
IV
-1
tr
an
sc
rip
tio
n 
(a
.u
.)
 Striatum
 Cortex
C
O
X 
IV
-1
tr
an
sc
rip
tio
n 
(a
.u
.)
B
Control NPA
0
1
2 **
**C
O
X 
IV
-2
tr
an
sc
rip
tio
n 
(a
.u
.)
 Striatum
 Cortex
C
O
X 
IV
-2
tr
an
sc
rip
tio
n 
(a
.u
.)
                        
                                          
C
Control NPA
0
1
2
*
**
C
O
X 
IV
-2
/C
O
X 
IV
-1
tr
an
sc
rip
tio
n
 Striatum
 Cortex
C
O
X 
IV
-2
/C
O
X 
IV
-1
tr
an
sc
rip
tio
n
 
Fig. 15 NPA induced a brain region-specific up-regulation of COX IV-2 transcripts. Primary striatal 
(grey columns) and cortical neurons (black columns) in culture were incubated in the presence of 10 mM 
NPA for 24 h. Total RNA was isolated and first strand cDNA was synthesized. A quantitative RT-PCR 
was performed and PCR products were analyzed using the relative ΔC
t 
method. The PCR signals of COX 
IV-1 (A) and COX IV-2 transcripts (B) were normalized to 18S rRNA or HPRT and compared with 
untreated cells. In (C), the ratio of COX IV-2 to COX IV-1 transcripts is shown. Data represent means ± 
SEM (*p<0.05, **p<0.01, n = 7).  
 
4.3.3   NPA-induced increase of COX isoform IV-2 in striatal neurons was accompanied by 
elevated intracellular ATP levels  
To better understand the role of COX in mitochondrial energy production under toxic conditions, 
I studied the effect of NPA on the intracellular energy level by measuring the ATP content. 
Treatment of striatal and cortical neurons with 10 mM NPA for 24 h caused a change in the 
intracellular ATP content. An elevation by approximately 15% was observed in striatal neurons 
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and, on the contrary, a decrease of the intracellular ATP content occurred in cortical neurons 
(Fig.16A).
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Fig. 16 Intracellular levels of ATP and ROS production were altered after NPA treatment in 
primary neuronal culture depending on the brain region. Striatal (grey columns) and cortical neurons 
(black columns) were analyzed regarding the intracellular ATP (A) and ROS (B) levels. Data were 
normalized to ATP and ROS levels in control cells set 100% and represent means ± SEM (*p<0.05, n = 
5).  
 
4.3.4   NPA caused an elevation of the intracellular ROS level in striatal but not in cortical 
neurons 
With respect to the role of reactive oxygen species (ROS) in oxidative cell damage and death 
under toxic and degenerative conditions, I analyzed the intracellular ROS level in striatal and 
cortical neuronal cultures (Fig. 16B). Cortical neurons demonstrated only a marginal increase in 
the intracellular ROS content, whereas striatal neurons revealed a significant elevation of the 
ROS level by approximately two-fold (Fig. 16B).  
 
4.4 Discussion 
The application of NPA resembles one of the widely used toxin-induced models which have been 
generated in addition to transgenic and knock-in animal models to study the pathogenic 
mechanisms of Huntington’s disease (Ramaswamy et al. 2007). Despite the availability of 
different models, it is still unclear as to what renders the striatum and specifically medium spiny 
striatal neurons selectively and highly vulnerable in HD. One possible mechanism of cell death in 
mutant huntingtin transgenic and drug-induced mouse models involves mitochondrial 
abnormalities of neurons (Gu et al. 1996; Browne et al. 1997; Tabrizi et al. 1999; Schapira et al. 
1997; Gellerich et al. 2008). Medium spiny neurons of the basal ganglia are known to have 
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greater energy requirements than other brain cells. Additionally, these cells are more susceptible 
to mutations in the protein huntingtin which is accompanied by a higher vulnerability of mutant 
neurons than neurons from wild-type littermates. Mutant cells are more susceptible to 
mitochondria-mediated Ca2+-dysregulation, especially when challenged with energy-demanding 
stimuli (Oliveira et al. 2007). This, in turn, could explain why striatal neurons are most 
vulnerable in HD.  
To mimic mitochondrial dysfunction, NPA and other inhibitors of the mitochondrial respiratory 
chain are used both in vitro and in vivo to model acute insults, such as ischemia as well as 
neurodegenerative disorders including Huntington’s and Alzheimer’s disease (Geddes et al. 
2000; Beal 2005; Ayala et al. 2007). NPA as an inhibitor of succinate dehydrogenase (SDH), 
complex II of the mitochondrial electron transport chain, is known to cause an impairment of 
mitochondrial energy production in neural cells (Beal 2005; Ayala et al. 2007; Gu et al. 1996; 
Schapira et al. 1997). My findings of an increased neuronal death after NPA treatment are in 
agreement with the observation of a selective loss of striatal neurons after systemic application of 
NPA (Nishino et al. 1995). As shown previously for astrocytes (Singh et al. 2008), I also provide 
evidence of a more pronounced necrotic than apoptotic cell death. On the other hand, both 
necrosis and apoptosis are generally associated with impaired energy metabolism and could, 
therefore, explain the decreased survival of neural cells treated with NPA (Sawa et al. 2003). 
Indeed, an increased cell death after NPA treatment has been correlated with diminished energy 
production due to a decreased respiratory chain enzyme activity (Brouillet et al. 1999; Sawa et al. 
2003; Landles and Bates 2004; Marcinek 2004; Beal 2005; Perez-De La Cruz and Santamaria 
2006). Surprisingly, I observed elevated instead of decreased ATP levels. Thereby, my findings 
provide challenging evidence that energy collapse is not necessarily involved in apoptotic or 
necrotic neuronal cell death upon NPA treatment. 
An increased activity of the creatine kinase system was considered as a compensatory mechanism 
for the decreased ATP level under these circumstances (Kasparova et al. 2006). This is supported 
by data showing that dietary creatine supplementation delayed the behavioural and 
neuropathological phenotype and extended survival of transgenic HD mice (Andreassen et al. 
2001). Creatine has also been shown to be protective in mitochondrial toxin models of HD 
(Matthews et al. 1998). In the striatum of HD patients, a decreased creatine level was found 
(Sanchez-Pernaute et al. 1999), which correlated with the clinical symptoms. However, a modest 
increase in the activity of creatine kinase and a small decrease in the creatine level in HD animals 
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(Oláh et al. 2008) cannot result in significant increased ATP concentrations which I observed in 
NPA-treated striatal neurons and as it was also found in brain tissue of HD transgenic mice (Oláh 
et al. 2008).  
To understand the mechanisms responsible for the NPA-mediated increase in neuronal death 
irrespectively of an increased cellular energy level, I studied the structural and functional 
properties of COX, the terminal enzyme of the respiratory chain. Previously, I have shown by 
applying small interfering RNA (siRNA) against COX IV-2 that elevated COX isoform IV-2 
transcription levels are causally correlated with increased enzyme activity. Moreover, a switch 
in the COX subunit IV isoform expression could serve as an explanation as to why neurons 
would undergo apoptosis and necrosis irrespectively of an increased energy level. In this 
context, increased COX activity could provide NPA-treated neurons with increased ATP levels. 
However, there is a disadvantage which accompanies the elevated cellular energy levels based 
on increased COX activity. Generally, an increased COX activity is assumed to decrease 
oxidative stress by decreasing ROS production resulting from a block of the electron transfer at 
complex III and I (Cadenas et al. 1977). However, a recent report suggests that an elevation of 
COX activity is associated with increased ROS production (Dröse and Brandt 2008). Thus, a 
higher COX electron transfer rate onto oxygen causes the ubiquinone pool to be oxidized to a 
higher degree, thereby enabling complex III to transfer electrons to oxygen and to increase the 
oxygen radical production. In turn, elevated ROS production could explain increased necrotic 
cell death rates as recently shown for NPA-treated striatal astrocytes (Singh et al. 2008). Striatal 
but not cortical neurons demonstrated a similar chain of features and events beginning with 
increased COX IV-2 transcription levels including an increased intracellular ATP content at the 
expense of higher ROS levels which finally leads to higher necrotic and apoptotic neuronal 
death rates. Thus, my data could serve as an explanation as to why neurons of specific brain 
regions are more prone than others to cell death under toxic and degenerative conditions.  
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5.  General Discussion 
Mitochondria are involved in energy maintenance and regulation of cell death pathways and play 
therefore, a pivotal role in the regulation of cell survival. Malfunctioning of mitochondria is often 
associated with toxic and degenerative processes in the CNS. In HD, a massive loss of medium 
spiny neurons in the striatum is observed, whereas the cerebral cortex is only moderately 
influenced (Graveland et al. 1985). The cause and mechanism behind the vulnerability of spiny 
neurons in striatum is not fully understood. Researchers have elucidated the role of mitochondrial 
abnormalities in generation of cell atrophy of neurons in mutant huntingtin transgenic and toxic-
induced mouse models (Schapira et al. 1997; Browie et al. 1997). To divulge the mitochondrial 
abnormalities, 3-nitropropionic acid (NPA) is used as an in vitro and in vivo model for HD. The 
effect of NPA on astrocytes and neurons involving the regulation of mitochondrial function is 
still a matter of investigation. Although, neurons are considered to undergo the changes by toxic 
assault severely, it recently became more evident that astrocytes also play a crucial role for 
neuronal survival under toxic and degenerative conditions (Margakis et al. 2006; Kipp et al. 
2006). My results revealed reduced astrocyte viability after NPA treatment. These data support 
the observation of a selective loss of striatal astrocytes after systemic NPA application (Nishino 
et al. 1995). In this study, I characterized the mode of cell death as pronounced necrosis instead 
of apoptosis in astrocytes. This observation was also supported by results on HD and NPA-
induced toxicity by Sawa et al. (2003). Generally, an increased cell death after NPA treatment 
has been linked to a decay of energy production. This energy failure is correlated to diminished 
respiratory chain enzyme activity (Beal 2005; Sawa et al. 2003). Surprisingly, I observed 
elevated instead of decreased ATP levels with increased cell death. Data showing partially 
inhibited SDH, after 3 mM NPA treatment for 4 hours indicate an incomplete blockage of 
mitochondrial energy metabolism by NPA (Esfiandri et al. 1997) with a fully functional complex 
I as an electron entry route, thereby supporting my data. In addition, Dringen and colleagues 
(Wiesinger et al. 1997) considered glycogen in astrocytes as a store for generating lactic acid 
rather than glucose. As in my experiments I have observed minor decrease of glycogen content in 
striatal astrocytes after NPA treatment it can be suggested that glycogen acts as a source for 
anaerobic ATP generation.  Moreover, ATP regulation was correlated with COX activity (Horvat 
et al. 2006), suspected involvement of this terminal enzyme of the mitochondrial electron 
transport chain was verified by the transcription pattern of COX subunit IV isoforms along with 
the kinetic characteristics of this enzyme. The NPA treatment caused an elevated catalytic 
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activity by enzyme due to a switch in COX subunit IV isoforms from COX IV-1 to COX IV-2 in 
striatal astrocytes. In control conditions, astrocytes demonstrate marginal transcription of COX 
IV-2 but ubiquitous transcription of COX isoform IV-1. The changes of the catalytic properties of 
COX can be explained by an abolition of ATP/ADP binding to the N-terminus of COX subunit 
IV (Arnold et al. 1997; Horvat et al. 2006). It indicates a crucial role for COX in sensing the 
cellular energy level and being able to couple it to mitochondrial ATP production (Horvat et al. 
2006). Application of small interfering RNA (siRNA) against COX IV-2 in astrocytes showed 
prevention of elevation of COX isoform IV-2 transcription level. The knockdown of COX IV-2 
revealed its association with ROS and necrosis. A previous study postulated that an abolition of 
the allosteric COX inhibition at high ATP/ADP levels could cause an increased production of 
reactive oxygen species (ROS) due to an elevated mitochondrial membrane potential (Lee et al. 
2001). Thus, my finding of NPA-mediated COX isoform IV-2 transcription, which prevents from 
the allosteric COX inhibition by ATP, supports the role for COX isoform IV-2 in oxidative stress. 
In support of my data, a recent report suggests a role for an elevation of COX activity in ROS 
production (Dröse and Brandt, 2008). The authors showed higher COX electron transfer onto 
oxygen that causes the ubiquinone pool to be oxidized to a higher degree, thereby enabling 
complex III to transfer electrons to oxygen and increase the oxygen radical production. Based on 
my study and the important role of COX IV isoforms, I performed NPA treatment on striatal and 
cortical neurons for 24 hours. A reduction of viability by almost 50% in striatal neurons after 
NPA treatment clearly exhibits that neurons are more vulnerable to NPA assault than astrocytes. 
My observations also revealed a brain region-specific NPA-mediated toxicity in neurons, which 
reflected the results of a study on HD brain, where striatal neurons were found to be depleted in 
higher amount than cortical neurons (Heinsen et al. 1994). Similar to striatal astrocytes, in striatal 
neurons, NPA treatment led to higher ATP levels at the expense of elevated ROS production and 
increased transcription of COX IV-2, but cortical neurons did not evoke similar kind of features. 
Brain region differences were also observed in other study where it was exhibited that many of 
the proteins that were differentially expressed and associated with neurotransmission in HD 
etiology in the striatum are up-regulated, while the majority of the expressed proteins in the 
cortex are down-regulated (Liu et al. 2007). My findings suggest that upon NPA treatment, 
apoptotic or necrotic neuronal cell death can progress without energy collapse. In favour of this 
theory, recently, higher ATP content was also reported in brain tissue from transgenic HD mice 
(Oláh et al. 2008). An increased activity of the creatine kinase system was also considered as a 
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compensatory mechanism for the decreased ATP level under these circumstances (Kasparova et 
al. 2006). Creatine has also been shown to be protective in mitochondrial toxin models of HD 
(Matthews et al. 1998). Cortical neurons displayed decreased transcription of COX IV-2 and 
decreased ATP content after the treatment with NPA for 24 hours. Direct COX activity 
measurements were not performed on neurons, because of a lack of a sufficient amount of cells to 
isolate mitochondria. But, taking COX isoform IV-2 transcription and COX activity correlation 
in astrocytes into consideration, it can be suggested that enhanced COX IV-2 transcription leads 
to higher ATP in striatal neurons, whereas lesser transcription in cortex is responsible for the 
lesser ATP.  
            This study clearly manifests the involvement of COX isoforms in NPA-induced toxicity in a 
brain region-specific manner. The brain region-specificity has also been reported in other studies 
where it is suggested that untreated striatal mitochondria may not differ from cortical ones but, 
when challenged with different stressors, striatal mitochondria may be more sensitive than 
cortical mitochondria (Dagani et al. 1984; Brustovetsky et al. 2003). Thus, an enhanced 
sensitivity to metabolic perturbation caused by COX isoform IV-2 in striatal mitochondria could 
contribute substantially to selective neuronal vulnerability in this brain region. Taken these 
previous studies and my data together into account, I suggest that neurons of specific brain 
regions are more prone than others to cell death under toxic and degenerative conditions due to 
differences in their mitochondrial property.    
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6.  Summary and Conclusion 
          Mitochondrial dysfunction leading to neurodegenerative diseases involves structural and 
functional changes of respiratory chain enzyme complexes. The data shown here manifested the 
effect of 3-nitropropionic acid (NPA), a mitochondrial toxin and in vitro model of Huntington’s 
disease (HD), on mitochondrial regulation and function which adds another evidence for COX as 
a respiratory chain enzyme to be an important participant in a neurodegenerative disease. With 
respect to the potential role of COX in toxin-induced cell death and degenerative diseases, I 
particularly aimed to analyze the expression of the COX subunit IV isoform and related it to 
functional consequences for the survival of striatal astrocytes and neurons. Although it is well-
known that NPA leads to an impairment of the cellular energy status, I found increased ATP 
levels in NPA-treated striatal astrocytes. This effect could be explained by an alteration of the 
expression pattern of COX subunit IV isoforms after 48 h of treatment of astrocytes with 10 mM 
NPA. The antidromic change caused by a switch of COX IV isoforms in striatal astrocytes led to 
a higher enzyme activity at the expense of a higher mitochondrial peroxide production. The 
resulting increased oxidative stress could, at least in part, explain the increased necrotic death of 
NPA-treated cells. The application of a siRNA-mediated knock-down system supported the 
causal link between the COX IV-2 expression and increased necrotic cell death due to elevated 
ROS production. The underlying mechanism of this regulatory process involves the binding of 
ATP to COX subunit IV-1 in the presence of a high ATP/ADP ratio, thereby causing an allosteric 
inhibition of COX, which is abolished by the expression of COX isoform IV-2. Overall, neurons 
showed a higher vulnerability towards NPA-mediated toxicity than astrocytes. Striatal but not 
cortical neurons demonstrated a similar chain of features and events beginning with increased 
transcription of COX isoform IV-2 accompanied by elevated ATP and ROS.    
            In conclusion, I demonstrated the crucial role of COX isoform IV-2 for the development of 
oxidative stress after NPA treatment leading to elevated necrosis in astrocytes, which could affect 
proper astroglia function under pathological conditions and, in turn, indirectly contribute to 
reduction of neuronal survival. Along with this, the fact of different brain regions responding 
differently to toxic conditions was highlighted and could explain why striatal neurons are more 
prone to death under intoxication of NPA. 
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7.  Outlook and future perspective 
In the last few years, the focus on mitochondria has unraveled defects of mitochondrial 
metabolism and their deleterious effect on cell function and survival, especially in highly energy-
dependent tissues such as the brain. There is strong evidence from genetics and transgenic mouse 
models that mitochondrial dysfunction results in neurodegeneration and may contribute to the 
pathogenesis of Alzheimer's disease, Parkinson's disease, and Huntington’s disease, amyotrophic 
lateral sclerosis, hereditary spastic paraplegia, and cerebellar degenerations. The involvement of 
enzyme complexes of the ETC has been reported in several studies as a cause of progressive 
degeneration of brain cells. Additionally, an emerging importance and contribution of glial cells, 
especially astrocytes, has bee postulated for the maintenance of neuronal function and survival. 
This drifted mitochondrial research towards the exploration of their involvement in astrocyte-
mediated neurodegeneration. Based on my study on COX IV involvement in the in vitro model of 
Huntington’s disease, I assume that COX IV subunit can be an important player in Huntington’s 
disease as well as other neurological diseases where close nexus have been shown between cell 
degeneration and oxidative stress. The study of COX IV in the context with different brain cell 
types and brain region-specificity can give a deeper insight in mitochondria-regulated molecular 
mechanisms and pathways leading to the neurodegeneration developed in specific parts of the 
brain. Increased intracellular ATP content after the NPA assault in my study provides a 
challenging task to explore a mechanism, where energy collapse is not necessarily involved in 
apoptotic or necrotic neuronal cell death.  
In my opinion, exploration of the role of COX IV in other diseases can provide the development 
of therapies that target basic mitochondrial processes such as energy metabolism and free radical 
generation or specific interactions of disease-related proteins with mitochondria which hold great 
promise. Nevertheless, future studies of neurodegeneration should focus on local astroglia 
considering not only their basal supportive function for neurons but equally deciphering the 
action of toxins and pathological processes on this cell type. More emphasis on stabilizing and 
improving astrocytic function may provide a tremendous impact on neuronal survival in the 
brain.  
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Zusammenfassung und Schlußfolgerung 
 
          Mitochondriale Fehlfunktionen, die zu neurodegenerativen Erkrankungen führen, involvieren 
strukturelle und funktionelle Veränderungen der Enzymkomplexe der mitochondrialen 
Atmungskette. Die hier gezeigten Ergebnisse zeigen den Effekt von 3-Nitropropionsäure (NPA), 
eines mitochondrialen Toxins und in vitro Models für Morbus Huntington (HD), auf die 
Regulation der Funktion von Mitochondrien. Dies ist ein weiterer Hinweis, dass die COX als 
wichtiges Atmungskettenenzym in neurodegenerative Erkrankungen involviert ist. Im Hinblick 
auf die potentielle Rolle der COX in toxin-induziertem Zelltod und degenerativen Erkrankungen 
war mein Ziel, die Expression der COX Untereinheit IV Isoform im Zusammenhang zu den 
entsprechenden funktionellen Konsequenzen für die Überlebensfähigkeit striataler Astrozyten 
und Neurone zu analysieren. Obwohl bekannt ist, dass NPA zu einer Verschlechterung des 
zellulären Energiestatus führt, beobachtete ich einen Anstieg des ATP Spiegels in NPA-
behandelten striatalen Astrozyten. Dieser Effekt konnte auf eine Veränderung des 
Expressionsverhaltens der COX Untereinheit IV Isoform nach 48 h Behandlung der Astrozyten 
mit 10 mM NPA zurückgeführt werden. Die antidromische Veränderung der COX Isoformen IV-
1 und IV-2, die einen Switch der COX IV Isoformen in striatalen Astrozyten hervorrief, führte zu 
einer gesteigerten Enzymaktivität zu Lasten einer erhöhten mitochondrialen Peroxidproduktion. 
Die resultierende Steigerung des oxidativen Stresses kann, zumindest teilweise, den erhöhten 
nekrotischen Zelltod NPA-behandelter Zellen erklären. Die Anwendung eines siRNA-
vermittelten Knock-down-Systems unterstützte den kausalen Zusammenhang zwischen der COX 
IV-2 Expression und gesteigertem nekrotischen Zelltod infolge erhöhter ROS-Produktion. Der 
dem zugrunde liegende Mechanismus dieses Regulationsprozesses involviert die Bindung von 
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ATP an die COX-Untereinheit IV-1 in Gegenwart eines hohen ATP/ADP-Spiegels, was zu einer 
allosterischen Hemmung der COX führt, die durch die COX IV-2 Expression aufgehoben wird.  
 Neurone zeigen allgemein eine höhere Vulnerabilität gegenüber NPA als Astrozyten. Striatale, 
allerdings nicht kortikale, Neurone zeigten ähnliche Befunde, beginnend mit einer gesteigerten 
Transkription der COX Isoform IV-2, die von gesteigerten ATP- und ROS-Niveaus begleitet 
wurde. 
 Zusammenfassend konnte ich die bedeutende Rolle der COX Isoform IV-2 für die Entwicklung 
von oxidativem Stress und nekrotischem Zelltod nach NPA-Behandlung in Astrozyten zeigen. 
Dies könnte astrogliale Funktionen unter pathologischen Bedingungen beeinträchtigen und 
dementsprechend das neuronale Überleben indirekt beeinflussen. Dies unterstützt auch die 
unterschiedliche Reaktion unterschiedlicher Gehirnregionen auf toxische Bedingungen und 
könnte erklären, warum die Neurone des Striatums am stärksten dem Zelltod durch NPA 
unterliegen als Neurone anderer Gehirnregionen.  
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